Nothing Special   »   [go: up one dir, main page]

WO1997020556A1 - Method for treating pain - Google Patents

Method for treating pain Download PDF

Info

Publication number
WO1997020556A1
WO1997020556A1 PCT/US1996/019390 US9619390W WO9720556A1 WO 1997020556 A1 WO1997020556 A1 WO 1997020556A1 US 9619390 W US9619390 W US 9619390W WO 9720556 A1 WO9720556 A1 WO 9720556A1
Authority
WO
WIPO (PCT)
Prior art keywords
thiadiazol
tetrahydro
methylpyridine
branched
azabicyclo
Prior art date
Application number
PCT/US1996/019390
Other languages
French (fr)
Other versions
WO1997020556A9 (en
Inventor
Charles H. Mitch
Harlan E. Shannon
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP09521436A priority Critical patent/JP2000501711A/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Priority to PL96327144A priority patent/PL327144A1/en
Priority to HU0000110A priority patent/HUP0000110A3/en
Priority to NZ324594A priority patent/NZ324594A/en
Priority to CA002239732A priority patent/CA2239732A1/en
Priority to IL12478696A priority patent/IL124786A0/en
Priority to AU11476/97A priority patent/AU715645B2/en
Priority to KR1019980704268A priority patent/KR19990071977A/en
Priority to EA199800535A priority patent/EA199800535A1/en
Priority to EP96942906A priority patent/EP0866702A4/en
Publication of WO1997020556A1 publication Critical patent/WO1997020556A1/en
Publication of WO1997020556A9 publication Critical patent/WO1997020556A9/en
Priority to NO982582A priority patent/NO982582L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a method for using azacyclic, azabicyclic, or tetrahydropyridine compounds for treating pain.
  • This invention relates to a therapeutic combination of compounds to provide analgesic activity.
  • More active analgesic combinations effects are in constant demand because they offer the attractive possibility of relieving pain with reduced dosages, thereby diminishing the expected side effects and toxicity that would otherwise result from higher dosages. It would be particularly desirable to acquire a synergistic combination effect.
  • Such a composition is the subject of the present invention.
  • the present invention provides a method for treating pain comprising administering to a patient in need thereof, an anagesic composition comprising a compound of Formula I
  • X is oxygen or sulphur
  • R is hydrogen, amino, halogen, -CHO, -N0 2 , -OR 4 , -SR 4 , -SOR 4 ,
  • R 4 is straight or branched C ⁇ - 15 -alkyl, straight or branched C 2 - 15 - alkenyl, straight or branched C.
  • Y is a 5 or 6 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched C ⁇ _ 6 -alkyl, phenyl or benzyl, or which heterocyclic group is optionally fused with a phenyl group; and G i ⁇ selected from one of the following azabicyclic rings
  • R 1 and R 2 may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C ⁇ - 5 -alkyl, straight or branched C 2 - 5 alkenyl, straight or branched C 2 - 5 -alkynyl, straight or branched C _ ⁇ o-alkoxy, straight or branched C 1 -.
  • R 3 is H, straight or branched C ⁇ - 5 -alkyl, straight or branched C 2 - 5 -alkenyl or straight or branched C 2 - 5 ⁇ alkynyl; n is 0, 1 or 2; m is 0, 1 or 2; p is 0, 1 or 2; q is 1 or 2; and is a single or double bond; or a pharmaceutically acceptable salt thereof; and a nonsteroidal anti-inflammatory drug in a weight ratio of Formula I to nonsteroidal anti-inflammatory drug of from about 1 to about 1000.
  • the present invention provides a method for treating pain comprising administering to a patient in need thereof, an anagesic composition comprising a compound of Formula II
  • Z 1 ' is oxygen or sulphur
  • R' is hydrogen, halogen, amino, -NHCO-R 2 ' , C 3 - 7 -cycloalkyl, C 4 - 10 ⁇ (cycloalkylalkyi) , -Z 2 ' -C 3 _ 7 -cycloalkyl optionally substituted with C ⁇ - 6 -alkyl, -Z 2 ' -C 4 -. 10 - (cycloalkylalkyi) , -Z 2 '-C 4 _ ⁇ o- (cycloalkenylalkyl) , -Z 2 '-C 4 _ ⁇ o- (methylenecycloalkyl-alkyl) ,
  • Z 2 ' , Z 3 ' , and Z 4 ' independently are oxygen or sulphur
  • R ' , R 3 ' and R 4 ' independently are straight or branched C ⁇ - 15 -alkyl, straight or branched C 2 -i 5 -alkenyl, straight or branched C 2 -i 5 -alkynyl, each of which is optionally substituted with halogen(s) , -OH, -CN, -CF 3 , -SH, -COOH, -NH-R 2 ' , -NR 2 'R 3 ', Ci- 6 alkyl ester, one or two phenyl, phenoxy, benzoyl or benzyloxycarbonyl wherein each aromatic group is optionally substituted with one or two halogen, -CN, C ⁇ _ 4
  • R 5 ' and R 6 ' may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C 1 - 5 - alkyl, straight or branched C 2 - 5 ⁇ alkenyl, straight or branched C 2 - 5 *-alkynyl, straight or branched Ci-irj-alkoxy, straight or branched C ⁇ - 5 -alkyl substituted with -OH, -OH, halogen, -NH 2 or carboxy;
  • R 1 ' is hydrogen, straight or branched C ⁇ - 5 -alkyl, straight or branched C 2 - 5 ⁇ alkenyl or straight or branched C 2 - 5 -alkynyl; or a pharmaceutically acceptable salt or solvate thereof; and one or more nonsteroidal anti-inflammatory drug in a weight ratio of Formula II to nonsteroidal anti- inflammatory drug of from about 1 to about 1000.
  • Preferred NSAIDS include, but are in no way limited to salicylates such a ⁇ aspirin, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
  • Especially preferred NSAIDS include aspirin, ibuprofen, and naproxen.
  • Alternative preferred NSAIDS include ibuprofen and naproxen.
  • Alternative particularly preferred NSAIDS include ibuprofen.
  • the invention further provides a composition for treating pain comprising a compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and a a nonsteroidal anti-inflammatory drug in a weight ratio of Compound to a nonsteroidal anti-inflammatory drug of from about 1 to about 1000.
  • the present invention provides a method for treating pain comprising administering to a patient in need thereof, an anagesic composition comprising a compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and acetaminophen in a weight ratio of Compound to acetaminophen of from about 1 to about 1000.
  • composition for treating pain comprising an analgesic dose of a compound selected from the group consisting of Formula I
  • X is oxygen or sulphur;
  • R is hydrogen, amino, halogen, -CHO, -N0 2 , -OR 4 , -SR 4 , -SOR 4 , -SO 2 R 4 , C 3 - 7 -cycloalkyl, C 4 - 8 - (cycloalkylalkyi) , -Z-C 3 -7- cycloalkyl, and -Z-C 4 - 8 - (cycloalkylalkyi) wherein R 4 is straight or branched C ⁇ - 15 -alkyl, straight or branched C 2 - 15 - alkenyl, straight or branched C 2 -i 5 -alkynyl, each of which is optionally substituted with one or more halogens, -CF 3 , -CN, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C ⁇ - 4 -alkyl
  • Y is a 5 or 6 membered heterocyclic group containing one to four N, 0 or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched C ⁇ _ 6 -alkyl, phenyl or benzyl, or which heterocyclic group is optionally fused with a phenyl group; and G is selected from one of the following azabicyclic rings
  • R 1 and R 2 may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C 1 -.
  • R 3 is H, straight or branched C ⁇ _ 5 -alkyl, straight or branched C 2 - 5 -alkenyl or straight or branched C 2 - 5 -alkynyl; n is 0, 1 or 2; m is 0, 1 or 2; p is
  • Z 1 ' is oxygen or sulphur
  • R' is hydrogen, halogen, amino, -NHCO-R 2 ' , C 3 _ 7 -cycloalkyl,
  • Z 2 ' , Z 3 ' , and Z 4 ' independently are oxygen or sulphur
  • R 2 ' , R 3 ' and R 4 ' independently are straight or branched C ⁇ _i 5 -alkyl, straight or branched C 2 -i 5 -alkenyl, straight or branched C 2 -i 5 *-alkynyl, each of which is optionally substituted with halogen(s) , -OH, -CN, -CF 3 , -SH, -COOH, -NH-R 2 ', -NR 2 'R 3 ', C ⁇ _ 6 alkyl ester, one or two phenyl, phenoxy, benzoyl or benzyloxycarbonyl wherein each aromatic group is optionally substituted with one or two halogen, -CN, C ⁇
  • a preferred composition is a weight ratio of Compound to acetaminophen of from about 1 to about 100.
  • An especially preferred ratio is from about 1 to about 30.
  • a further preferred ratio may be from about 1 to about 10.
  • a final preferred ratio may be from about 1 to about 3.
  • the invention further provides a composition for treating pain comprising a Compound selected from the group consisting of Formula I and Formula II or a pharmaceutically acceptable salt or solvate thereof and a acetaminophen in a weight ratio of Compound to acetaminophen of from about 1 to about 1000.
  • the present invention provides a composition for treating pain comprising a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt thereof; and a central alpha-adrenergic active compound in a weight ratio of Compound to central alpha-adrenergic active compound of from about 1 to about 1000.
  • a preferred composition is a weight ratio of Compound to central alpha-adrenergic active compound of from about 1 to about 100.
  • An especially preferred ratio is from about 1 to about 30.
  • a further preferred ratio may be from about 1 to about 10.
  • a particularly preferred central alpha- adrenergic active compound is Clonidine or a pharmaceutically acceptable salt thereof.
  • the chemical name for clonidine is 2- (2, 6-dichlorophenylamino) -2- imidazoline.
  • the invention further provides a method for treating pain comprising administering an effective amount of a compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and a central alpha-adrenergic active compound in a weight ratio of Compound to central alpha- adrenergic active compound of from about 1 to about 1000.
  • the present invention provides a method for treating pain comprising administering to a patient in need thereof, an anagesic composition comprising a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and one or more opioid compounds in a weight ratio of Compound to an opioid active compound of from about 1 to about 1000.
  • an anagesic composition comprising a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and one or more opioid compounds in a weight ratio of Compound to an opioid active compound of from about 1 to about 1000.
  • a preferred composition is a weight ratio of
  • Compound to opioid compound of from about 1 to about 100.
  • An especially preferred ratio is from about 1 to about 30.
  • a further preferred ratio may be from about 1 to about 10.
  • Preferred an opioid compounds are morphine, codeine, eperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton' s cocktail.
  • Especially preferred opioid compounds are selected from the group consisting of hydromorphone, hydrocodone, meperidone, buprenorphine, butorphenol, nalbuphine, pentazocine, oxymorphine, oxycodone, levorphanol, fentanyl, and alphaprodine.
  • Particularly preferred opioid compounds are selected from the group consisting of propoxyphene, methadone, morphine, hydrocodone, hydromorphine, and codeine.
  • the especially particularly preferred opioid compounds are selected from morphine and codeine.
  • the invention further provides a composition for treating pain comprising a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and a one or more opioid compounds in a weight ratio of Compound to opioid compound of from about 1 to about 1000.
  • NSAIDS represents a nonsteroidal anti-inflammatory drug which can be identified as such by the skilled artisan.
  • the Merck Manual, 16th Edition, Merck Research Laboratories (1990) pp 1308 - 1309 provide well known examples of NSAIDS.
  • the term is intended to include, but is not limited to salicylates such as aspirin, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
  • NSAIDS include aspirin, ibuprofen, and naproxen.
  • NSAIDS are indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
  • Particularly preferred NSAIDS include aspirin and ibuprofen.
  • the salicylates may include acetylsalicylic acid, sodium acetylsalicylic acid, calcium acetylsalicylic acid, salicylic acid, and sodium salicylate.
  • An especially preferred NSAID is ibuprofen.
  • acetaminophen shall have the art accepted meaning and refers to N-(4- Hydroxyphenyl) acetamide and ' -hydroxyacetanilide.
  • the compound is claimed in U.S. Patent No. 2,998,450 and is known to the skilled artisan.
  • central alpha-adrenergic active compounds represents a compound having central alpha-adrenergic receptor activity.
  • the most preferred central alpha-adrenergic active compound is clonidine or a pharmaceutically acceptable salt thereof having the chemical name: 2- (2, 6-dichlorophenylamino) -2- imidazoline. Clonidine is known to be useful for treating hypertension. see Physicians' Desk Reference, 45th Ed. (1991) p. 673.
  • opioid represents opioid analgesics and antagonists including natural opioid analgesics, synthetic opioid analgesics, opioid antagonists and opioid agonist-antagonists.
  • Preferred an opioid compounds are selected from the group consisting of morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton's cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine. More preferred opioid compounds are selected from the group consisting of codeine, nabuphine, naloxone, and naltrexone.
  • Preferred an opioid compounds are morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton's cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine.
  • Especially preferred opioid compounds are selected from the group consisting of hydromorphone, hydrocodone, meperidone, buprenorphine, butorphenol, nalbuphine, pentazocine, oxymorphine, oxycodone, levorphanol, fentanyl, and alphaprodine.
  • Particularly preferred opioid compounds are selected from the group consisting of propoxyphene, methadone, morphine, hydrocodone, hydromorphine, and codeine.
  • the especially particularly preferred opioid compounds are selected from morphine and codeine.
  • a group of compounds having muscarinic cholinergic activity can be particular useful for treating pain when used in combination with non-steroidal antiinflammatory agents (NSAIDS) . More specifically, the invention provides a method of treating pain in humans using a specified azacyclic, azabicyclic or tetrahydropyridine compounds (collectively referred to herein as "selected muscarinic compounds") in combination with a NSAIDS to provide a synergistic effect.
  • NSAIDS non-steroidal antiinflammatory agents
  • the invention provides a method of treating pain in humans using a specified Selected Muscarinic Compounds in combination with acetaminophen to provide a synergistic effect.
  • the invention provides a method of treating pain in humans using Selected Muscarinic Compounds in combination with a central alpha-adrenergic active compound to provide a synergistic effect.
  • composition of this invention a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof and NSAIDS compound are combined in a weight ratio of Compound to NSAIDS of from about 1 to about 1000.
  • a preferred composition is a weight ratio of Compound to NSAIDS of from about 1 to about 100.
  • An especially preferred ratio is from about 1 to about 30.
  • a further preferred ratio may be from about 1 to about 10.
  • a final preferred ratio may be from about 1 to about 3.
  • composition of this invention a Compound of Formula or Formula II and acetaminophen are combined in a weight ratio of Formula I or Formula II to acetaminophen of from about 1 to about 1000.
  • a preferred composition is a weight ratio of Formula I or Formula II to acetaminophen of from about 1 to about 100.
  • An especially preferred ratio is from about 1 to about 30.
  • a further preferred ratio may be from about 1 to about 10.
  • a final preferred ratio may be from about 1 to about 3.
  • the compounds of Formula I and Formula II are effective over a wide dosage range; however, it is desirable to administer a dosage that is as low as possible.
  • the amount of NSAIDS present in the composition is adjusted as described above in ratio to the Formula I or Formula II dosage.
  • the amount of acetaminophen present in the composition is adjusted as described above in ratio to the Formula I or Formula II dosage.
  • dosages per day of the Formula II compounds will normally fall within the range of about 0.005 to about 100 mg/kg of body weight and the acetaminophen in the composition would be from 3 to 1000 times this amount.
  • dosages per day of the Formula I compounds will normally fall within the range of about 0.005 to about 100 mg/kg of body weight and the NSAIDS in the composition would be from 3 to 1000 times this amount.
  • composition of thi ⁇ invention a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt thereof and one or more opioid compounds are combined in a weight ratio of Compound to opioid compound of from about 1 to about 1000.
  • a preferred composition is a weight ratio of Compound to opioid compound of from about 1 to about 100.
  • An especially preferred ratio is from about 1 to about 30.
  • a further preferred ratio may be from about 1 to about 10.
  • a final preferred ratio may be from about 1 to about 3.
  • the Compounds are effective over a wide dosage range; however, it is desirable to administer a dosage that is as low as possible.
  • the amount of opioid compound present in the composition is adjusted as described above in ratio to the Compound dosage. For example, dosages per day of the Formula I compounds will normally fall within the range of about 0.005 to about 100 mg/kg of body weight and the opioid compound in the composition would be from 3 to 1000 times this amount.
  • the amount of the Compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of Compound to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.
  • the present compounds are preferably administered orally to humans susceptible to or suffering from pain
  • the compound ⁇ may also be administered by a variety of other routes such as the transdermal, parenterally, subcutaneous, intranasal, intramuscular and intravenous routes.
  • Such formulations may be designed to provide delayed or controlled release using formulation techniques which are known in the art .
  • Transdermal formulations containing the composition claimed herein most preferably deliver the active substances in an effective amount for from about three days to about seven days. However, for chronic pain such as arthritis or cancer pain, a transdermal delivery of from about three days to up to about two weeks is desirable. Alternatively, it may be preferred to deliver the claimed compositions transdermally in an effective amount for from about one day to about three days .
  • treating includes prophylaxis of a physical and/or mental condition or amelioration or elimination of the developed physical and/or mental condition once it has been established or alleviation of the characteristic symptoms of such condition.
  • the compounds of Formula I and Formula II employed in the invention are not believed to act via the GABA/benzodiazepine, 5HT1A, or Dl receptor systems in humans. Rather, the activity of the present Formula I and Formula II compounds as analgesic agents is believed to be based upon modulation of muscarinic cholinergic receptors. However, the mechanism by which the present compounds function is not necessarily the mechanism stated supra . , and the present invention is not limited by any mode of operation.
  • Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically-acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science. 66, 2 (1977) which are known to the skilled artisan.
  • the compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
  • the route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, depot, subcutaneous, intravenous, intramuscular or intranasal, the oral route being preferred.
  • oral or parenteral e.g. rectal, transdermal, depot, subcutaneous, intravenous, intramuscular or intranasal, the oral route being preferred.
  • the dosage administered will, of course, vary depending on known factors such as the pharmacodynamic characteristics of the particular agent, and it smode and route of administration; age, health, and weight of the recipient; nature and extent of the symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired.
  • the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 100 mg/kg of body weight Formula I or Formula II compound and from about 0.6 to about 200 mg/kg of NSAIDS.
  • Compositions suitable for internal administration contain from about one half (0.5) milligrams to about 600 milligrams of active ingredient per unit.
  • the active ingredient will ordinarily be present in an amount of from about 0.5% to about 95% by weight based on the total weight of the composition.
  • the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 100 mg/kg of body weight Formula II compound and from about 0.6 to about 200 mg/kg of acetaminophen.
  • compositions include a compound of Formula I or Formula II or a pharmaceutically acceptable acid addition salt thereof and one or more NSAIDSs, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
  • a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
  • the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container.
  • the carrier When the carrier serves a ⁇ a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound.
  • the active compound can be adsorbed on a granular solid container for example in a sachet.
  • suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone.
  • the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents.
  • the formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
  • Typical compositions include a compound of Formula I or Formula II or a pharmaceutically acceptable acid addition salt thereof and acetaminophen, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
  • conventional techniques for the preparation of pharmaceutical compositions may be used, as described above.
  • a preferred composition is a weight ratio of Compound to central alpha-adrenergic active compound of from about 1 to about 100.
  • An especially preferred ratio is from about 1 to about 30.
  • a further preferred ratio may be from about 1 to about 10.
  • a final preferred ratio may be from about 1 to about 3.
  • the compounds of Formula I and Formula II are effective over a wide dosage range; however, it is desirable to administer a dosage that is as low as possible.
  • the amount of central alpha-adrenergic active compound present in the composition is adjusted as described above in ratio to the Formula I or Formula II dosage. For example, dosages per day of the Formula I compounds will normally fall within the range of about 0.005 to about 100 mg/kg of body weight and the central alpha-adrenergic active compound in the composition would be from 3 to 1000 times this amount.
  • the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 100 mg/kg of body weight Formula I or Formula II compound and from about 0.6 to about 200 mg/kg of central alpha-adrenergic active compound.
  • compositions include a compound of formula I or Formula II or a pharmaceutically acceptable acid addition salt thereof; and one or more central alpha- adrenergic active compounds, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
  • a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
  • conventional technique ⁇ for the preparation of pharmaceutical compo ⁇ ition ⁇ may be used.
  • the pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pre ⁇ sure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.
  • injectable solutions or suspen ⁇ ion ⁇ preferably aqueous solutions with the active compound dis ⁇ olved in polyhydroxylated castor oil.
  • Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
  • Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch.
  • a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
  • the Formula I or Formula II compounds are dispensed in unit form comprising from about 0.1 to about 100 mg in a pharmaceutically acceptable carrier per unit dosage.
  • compositions of this invention may be suitable for administration to an animal.
  • animals include both domestic animals, for example livestock, laboratory animals, and household pets, and non-domestic animals such as wildlife. More preferredly, the animal is a vertebrate.
  • a compound of this invention shall be administered to a mammal. It is especially preferred that the animal is a domestic mammal or a human. The most preferred mammal is a human. For such purposes, a compound of this invention may be administered as a feed additive.
  • Acetic acid-induced writhing A standard procedure for detecting and comparing the analgesic activity of different classes of analgesic drugs for which there is a good correlation with human analgesic activity is the prevention of acetic acid-induced writhing in mice.
  • Mice are subcutaneously administered various doses of the claimed composition and are injected injected intraperitoneally with acetic acid (0.5% solution, 10 ml/kg) 5 min prior to a designated observation period.
  • acetic acid (0.5% solution, 10 ml/kg
  • a "writhe" is indicated by whole body stretching or contraction of the abdomen during the observation period beginning 5 min after receiving the acetic acid. Inhibition of writhing behavior is demonstrative of analgesic activity.
  • Sciatic nerve ligation model Rats are anesthetized and a nerve ligation procedure performed. The common sciatic nerve is exposed and 4 ligatures tied loosely around it with about 1 mm spacing. One day to 10 weeks after surgery, the nocieeptive testing is performed. Responses to noxious heat are determined by placing the rats in a chamber with a clear glass floor and aiming at the plantar surface of the affected foot a radiant heat source from beneath the floor. Increased latency to withdraw the hindpaw is demonstrative of analgesic activity. Responses to normally innocuous mechanical stimuli is determined by placing the rats in a chamber with a screen floor and stimulating the plantar surface of the hind paw with graduated von Frey hairs which are calibrated by the grams of force required to bend them.
  • Rats with sciatic nerve ligation respond to lower grams of mechanical stimulation by reflexive withdrawal of the foot than unoperated rats. This response to stimuli which are normally innocuous is termed allodynia. Increases in the grams of mechanical force required to produce foot withdrawal is demonstrative of antiallodynic activity. See, Bennett, G.J. and Xie, Y.-K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107. See also, Lee, Y.-W., Chaplan, S.R. and Yaksh, T.L. :
  • Rats are anesthetized and when there is a loss of spontaneous movement the rats are injected subcutaneously in the dor ⁇ al ⁇ urface of the hindpaw with 50 ul of 5% formalin solution using a 30 gauge needle. Rats are then individually placed in an open Plexiglas chamber for observation, and within a maximum interval of 1 to 2 min, the animal displays recovery from anesthesia with spontaneous activity and normal motor function. Pain behavior is quantified by periodically counting the incidents of spontaneous flinching/shaking of the injected paw. The flinches are counted for 1-min periods at 1- to 2-, 5- to 6- and 5min intervals during the interval from 10 to 60 min. Inhibition of the pain behavior is demonstrative of an analgesic activity.
  • Brewer's yeast-induced hyperalgesia (Randall-Selitto Test) : To assess nocieeptive threshold in rats, ascending pressure is applied gradually to the paw with a motor driven weight of a Ugo Basile Analgesy Meter. Rats respond to the pressure by either pulling free of the device, struggling or vocalizing. Hyperalgesia is induced by a hind paw subplantar injection of 0.1 ml of 1% suspension of brewer's yeast in 0.9% saline. The composition of this invention is administered at varying times ( 0 - 4 hr) after injection of brewer's yeast and pressure threshold for the inflamed paw again determined at varying times.
  • mice Male mice are fasted for 16-22 hours and weighed. Mice weighing from about 18-22 grams at the time of testing are used for the following studies. All mice are dosed sequentially by the oral route with suspensions of a composition of this invention. Doses are coded using a code unknown to the observer.
  • a stock suspension of the test composition is prepared by mixing the active ingredients with about 40 mL of an aqueous vehicle containing about 2% Tween 80 (R) , a pharmacological dispersant and containing 100% polysorbate 80, and 1% by weight Methocel (R) MC powder, and containing 100% methylcellulose, in distilled water. The mixture may be sonicated for about 10 to about 15 seconds using an ultrasound sytem. All dosing suspensions are prepared by dilution of the stock suspension with Methocel/Tween 80. All suspensions are used within two hours of preparation.
  • mice treated with various doses of compound of Formula I or Formula II, composition or vehicle are injected intraperitoneally with a standard challenge dose of phenyl-p-benzoquinone 5 minutes prior to a designated observation period.
  • the pheyl-p-benzoquinone is prepared as about 0.1 mg/ml solution in about 5% by volume of ethanol in water.
  • the writhing dose is 1.25 mg/kg injected at a volume of about 0.25ml/10g.
  • a "writhe" is indicated by whole body stretching or contracting of the abdomen during an observation period beginning about five minutes after the phenyl-p- benzoquinone dose.
  • the solid line connecting the ED50 dosages of Formula I or Formula II (alone) and classical analgesic as claimed herein (alone) represents the "ED50 addition line" which indicates the expected location of the ED50's for Formula I or Formula II and classical analagesic combinations if simple additivity were to describe their combined effects.
  • the 95% confidence range for the ED50 addition line is shown by the area between the broken lines above and below the ED50 addition line.
  • Formula II and classical analgesic component of each fixed dosage ratio would be contained within or overlap the region of the ED50 addition line.
  • Combination ED50 ' s located significantly below the ED50 addition line would represent unexpectedly enhanced analgesic activity and combination ED50 ' s located above the line would represent unexpected diminished analgesic effect.
  • One method to establish the significance of such unexpected enhanced or diminished activity is to calculate the best fitting polynomial regression line to the observed ED50's using standard mathematical techniques.
  • compositions comprised of a compound of Formula I or Formula II and one or more classical analgesics provides a statistically significant synergistic analgesic effect.
  • Preferred compounds of Formula I for use in the analesic compositions are selected from the following:
  • Particularly preferred compounds of Formula I include:
  • More preferred compounds include the following: 3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO(2.2.2)OCTANE
  • the most especially preferred compound of Formula I is 3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL- -YL) -1- AZABICYCLO [2.2.2]OCTANE; or a pharmaceutically acceptable salt or solvate thereof.
  • Preferred compounds of Formula II for the analgesic composition are selected from the following:
  • TRANS-3- (3- (2-HEXENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
  • Especially preferred compounds include the following:
  • TETRAHYDRO-1-METHYLPYRIDINE or a pharmaceutically acceptable salt or solvate thereof.
  • Compound which are particularly preferred include:
  • METHYLPYRIDINE or a pharmaceutically acceptable salt or solvate thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Processing Of Meat And Fish (AREA)

Abstract

The present invention provides a method and composition for treating pain using a composition comprising an azabicyclic or tetrahydropyridine compound and a classical analgesic compound.

Description

METHOD FOR TREATING PAIN
The present invention relates to a method for using azacyclic, azabicyclic, or tetrahydropyridine compounds for treating pain.
This invention relates to a therapeutic combination of compounds to provide analgesic activity.
More active analgesic combinations effects are in constant demand because they offer the attractive possibility of relieving pain with reduced dosages, thereby diminishing the expected side effects and toxicity that would otherwise result from higher dosages. It would be particularly desirable to acquire a synergistic combination effect. Such a composition is the subject of the present invention.
The present invention provides a method for treating pain comprising administering to a patient in need thereof, an anagesic composition comprising a compound of Formula I
Figure imgf000003_0001
wherein
X is oxygen or sulphur;
R is hydrogen, amino, halogen, -CHO, -N02, -OR4, -SR4, -SOR4,
-SO2R4, C3-7-cycloalkyl, C4-8- (cycloalkylalkyi) , -Z-C3-7- cycloalkyl, and -Z-C4-8- (cycloalkylalkyi) wherein R4 is straight or branched Cι-15-alkyl, straight or branched C2-15- alkenyl, straight or branched C.2-i5-alkynyl, each of which is optionally substituted with one or more halogens, -CF3 , -CN, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, Cι_4-alkyl, Cι-4-alkoxy, -OCF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, Cι-4-alkyl, Cι-4-alkoxy, -OCF3, -CONH2 or -CSNH2; or R is -OR5Y, -SR5Y,
-0R5ZY, -SR5ZY, -0-R -Z- R5 or -S-R4-Z-R5 wherein Z is oxygen or sulphur, R5 is straight or branched C -15-alkynyl, and Y is a 5 or 6 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched Cι_6-alkyl, phenyl or benzyl, or which heterocyclic group is optionally fused with a phenyl group; and G iε selected from one of the following azabicyclic rings
Figure imgf000004_0001
wherein the thiadiazole or oxadiazole ring can be attached at any carbon atom of the azabicyclic ring; R1 and R2 may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched Cι-5-alkyl, straight or branched C2-5 alkenyl, straight or branched C2-5-alkynyl, straight or branched C _ιo-alkoxy, straight or branched C1-.5- alkyl substituted with -OH, OR4, halogen, -NH2 or carboxy; R3 is H, straight or branched Cι-5-alkyl, straight or branched C2-5-alkenyl or straight or branched C2-5~alkynyl; n is 0, 1 or 2; m is 0, 1 or 2; p is 0, 1 or 2; q is 1 or 2; and is a single or double bond; or a pharmaceutically acceptable salt thereof; and a nonsteroidal anti-inflammatory drug in a weight ratio of Formula I to nonsteroidal anti-inflammatory drug of from about 1 to about 1000.
The present invention provides a method for treating pain comprising administering to a patient in need thereof, an anagesic composition comprising a compound of Formula II
Figure imgf000005_0001
wherein
Z1' is oxygen or sulphur;
R' is hydrogen, halogen, amino, -NHCO-R2' , C3-7-cycloalkyl, C 4-10~ (cycloalkylalkyi) , -Z2' -C3_7-cycloalkyl optionally substituted with Cι-6-alkyl, -Z2' -C4-.10- (cycloalkylalkyi) , -Z2'-C4_ιo- (cycloalkenylalkyl) , -Z2'-C4_ιo- (methylenecycloalkyl-alkyl) ,
-NH-R2', -NR2'R3', -NH-OR2', phenyl, phenoxy, benzoyl, benzyloxycarbonyl, tetrahydronaphtyl, indenyl, X', R ' , -Z 'R2', -SOR2', -S02R2', -Z2'-R2'-Z3'-R3', _Z2•_R2' _z3 ' _R3 ' _z4' _ R4', -Z ,-R2'CO-R3',
-Z2'-R2'-C02-R3' , Z2'-R2,-02C-R3' , -Z2' -R2' -CONH-R3 ' , -Z2 ' -R2' - NHCOR3 ' ,
-Z2'-R2'-X' , -Z2'-R2'-Z3'-X' , wherein Z2' , Z3 ' , and Z4' independently are oxygen or sulphur, and R ' , R3 ' and R4' independently are straight or branched Cι-15-alkyl, straight or branched C2-i5-alkenyl, straight or branched C2-i5-alkynyl, each of which is optionally substituted with halogen(s) , -OH, -CN, -CF3, -SH, -COOH, -NH-R2' , -NR2'R3', Ci-6alkyl ester, one or two phenyl, phenoxy, benzoyl or benzyloxycarbonyl wherein each aromatic group is optionally substituted with one or two halogen, -CN, Cι_4-alkyl or Cι-4-alkoxy, and X' is a 5 or 6 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(ε) with straight or branched Cι-6- alkyl, phenyl, benzyl or pyridine, or a carbon atom in the heterocyclic group together with an oxygen atom form a carbonyl group, or which heterocyclic group is optionally fused with a phenyl group; and
R5' and R6' may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C1-5- alkyl, straight or branched C2-5~alkenyl, straight or branched C2-5*-alkynyl, straight or branched Ci-irj-alkoxy, straight or branched Cχ-5-alkyl substituted with -OH, -OH, halogen, -NH2 or carboxy; R1' is hydrogen, straight or branched Cι-5-alkyl, straight or branched C2-5~alkenyl or straight or branched C2-5-alkynyl; or a pharmaceutically acceptable salt or solvate thereof; and one or more nonsteroidal anti-inflammatory drug in a weight ratio of Formula II to nonsteroidal anti- inflammatory drug of from about 1 to about 1000.
Preferred NSAIDS include, but are in no way limited to salicylates such aε aspirin, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac. Especially preferred NSAIDS include aspirin, ibuprofen, and naproxen. Alternative preferred NSAIDS include ibuprofen and naproxen. Alternative particularly preferred NSAIDS include ibuprofen. The invention further provides a composition for treating pain comprising a compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and a a nonsteroidal anti-inflammatory drug in a weight ratio of Compound to a nonsteroidal anti-inflammatory drug of from about 1 to about 1000.
The present invention provides a method for treating pain comprising administering to a patient in need thereof, an anagesic composition comprising a compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and acetaminophen in a weight ratio of Compound to acetaminophen of from about 1 to about 1000.
A composition for treating pain comprising an analgesic dose of a compound selected from the group consisting of Formula I
Figure imgf000007_0001
wherein
X is oxygen or sulphur; R is hydrogen, amino, halogen, -CHO, -N02, -OR4, -SR4, -SOR4, -SO2R4, C3-7-cycloalkyl, C4-8- (cycloalkylalkyi) , -Z-C3-7- cycloalkyl, and -Z-C4-8- (cycloalkylalkyi) wherein R4 is straight or branched Cι-15-alkyl, straight or branched C2-15- alkenyl, straight or branched C2-i5-alkynyl, each of which is optionally substituted with one or more halogens, -CF3, -CN, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, Cι-4-alkyl, C -4-alkoxy, -OCF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, Cι_4-alkyl, Cι_4-alkoxy, -OCF3, -CONH2 or -CSNH2; or R is -OR5Y, -SR5Y,
-OR5ZY, -SR5ZY, -0-R -Z- R5 or -S-R4-Z-R5 wherein Z is oxygen or sulphur, R5 is straight or branched Cι-15-alkynyl, and Y is a 5 or 6 membered heterocyclic group containing one to four N, 0 or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched Cι_6-alkyl, phenyl or benzyl, or which heterocyclic group is optionally fused with a phenyl group; and G is selected from one of the following azabicyclic rings
Figure imgf000008_0001
wherein the thiadiazole or oxadiazole ring can be attached at any carbon atom of the azabicyclic ring; R1 and R2 may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C1-.5- alkyl, straight or branched C2-5 alkenyl, straight or branched C2-5-alkynyl, straight or branched Cι_]_o-alkoxy, straight or branched Cι_5-alkyl substituted with -OH, OR4, halogen, -NH2 or carboxy; R3 is H, straight or branched Cι_ 5-alkyl, straight or branched C2-5-alkenyl or straight or branched C2-5-alkynyl; n is 0, 1 or 2; m is 0, 1 or 2; p is
0, 1 or 2; q is 1 or 2; and is a single or double bond; and
Formula II
Figure imgf000009_0001
wherein
Z1' is oxygen or sulphur;
R' is hydrogen, halogen, amino, -NHCO-R2' , C3_7-cycloalkyl,
C4-10- (cycloalkylalkyi) , -Z2'-C3_7-cycloalkyl optionally substituted with Cι_6-alkyl, -Z2' -C4-10- (cycloalkylalkyi) ,
-Z2' -C4-.10- (cycloalkenylalkyl) , -Z2'-C4_ιo-
(methylenecycloalkyl-alkyl) ,
-NH-R2', -NR2'R3', -NH-OR2', phenyl, phenoxy, benzoyl, benzyloxycarbonyl, tetrahydronaphtyl, indenyl, X', R2' ,
-Z2'R2', -SOR2', -S02R2' -Z '-R2' ■3 ' . -R- _z2'_R2'_z3'_R3'_z4
R4', -Z '-R 'CO-R3',
-Z2' -R2' -C02-R3' , Z2' -R2' -O2C-R3 ' , -Z2'-R2'-CONH-R3' , -Z2'-R2'-
NHCOR3' ,
-Z2'-R2*-X', _z2'_R2'_z3*_χι f wherein Z2' , Z3 ' , and Z4' independently are oxygen or sulphur, and R2' , R3 ' and R4' independently are straight or branched Cι_i5-alkyl, straight or branched C2-i5-alkenyl, straight or branched C2-i5*-alkynyl, each of which is optionally substituted with halogen(s) , -OH, -CN, -CF3, -SH, -COOH, -NH-R2', -NR2'R3', Cι_6alkyl ester, one or two phenyl, phenoxy, benzoyl or benzyloxycarbonyl wherein each aromatic group is optionally substituted with one or two halogen, -CN, Cι-4-alkyl or C1-4-alkoxy, and X' is a 5 or 6 membered heterocyclic group containing one to four N, 0 or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched C -e- alkyl, phenyl, benzyl or pyridine, or a carbon atom in the heterocyclic group together with an oxygen atom form a carbonyl group, or which heterocyclic group is optionally fuεed with a phenyl group; and R5' and R6' may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C1-5- alkyl, straight or branched C2-5-alkenyl, straight or branched C2-5-alkynyl, straight or branched Cι-10-alkoxy, straight or branched Cι-5-alkyl substituted with -OH, -OH, halogen, -NH2 or carboxy; R1' is hydrogen, straight or branched Cι_5-alkyl, straight or branched C2-5-alkenyl or straight or branched C2-5-alkynyl; or a pharmaceutically acceptable salt or solvate thereof; and acetaminophen in a weight ratio of Compound to acetaminophen of from about 1 to about 1000.
A preferred composition is a weight ratio of Compound to acetaminophen of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
The invention further provides a composition for treating pain comprising a Compound selected from the group consisting of Formula I and Formula II or a pharmaceutically acceptable salt or solvate thereof and a acetaminophen in a weight ratio of Compound to acetaminophen of from about 1 to about 1000.
The present invention provides a composition for treating pain comprising a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt thereof; and a central alpha-adrenergic active compound in a weight ratio of Compound to central alpha-adrenergic active compound of from about 1 to about 1000.
A preferred composition is a weight ratio of Compound to central alpha-adrenergic active compound of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10.
A particularly preferred central alpha- adrenergic active compound is Clonidine or a pharmaceutically acceptable salt thereof. The chemical name for clonidine is 2- (2, 6-dichlorophenylamino) -2- imidazoline.
The invention further provides a method for treating pain comprising administering an effective amount of a compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and a central alpha-adrenergic active compound in a weight ratio of Compound to central alpha- adrenergic active compound of from about 1 to about 1000.
The present invention provides a method for treating pain comprising administering to a patient in need thereof, an anagesic composition comprising a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and one or more opioid compounds in a weight ratio of Compound to an opioid active compound of from about 1 to about 1000. A preferred composition is a weight ratio of
Compound to opioid compound of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10. Preferred an opioid compounds are morphine, codeine, eperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton' s cocktail. naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine.
Especially preferred opioid compounds are selected from the group consisting of hydromorphone, hydrocodone, meperidone, buprenorphine, butorphenol, nalbuphine, pentazocine, oxymorphine, oxycodone, levorphanol, fentanyl, and alphaprodine.
Particularly preferred opioid compounds are selected from the group consisting of propoxyphene, methadone, morphine, hydrocodone, hydromorphine, and codeine. The especially particularly preferred opioid compounds are selected from morphine and codeine.
The invention further provides a composition for treating pain comprising a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and a one or more opioid compounds in a weight ratio of Compound to opioid compound of from about 1 to about 1000.
The term "NSAIDS", as used herein, represents a nonsteroidal anti-inflammatory drug which can be identified as such by the skilled artisan. For example, the Merck Manual, 16th Edition, Merck Research Laboratories (1990) pp 1308 - 1309 provide well known examples of NSAIDS. The term is intended to include, but is not limited to salicylates such as aspirin, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac. Especially preferred NSAIDS include aspirin, ibuprofen, and naproxen. Alternative preferred NSAIDS are indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac. Particularly preferred NSAIDS include aspirin and ibuprofen. The salicylates may include acetylsalicylic acid, sodium acetylsalicylic acid, calcium acetylsalicylic acid, salicylic acid, and sodium salicylate. An especially preferred NSAID is ibuprofen.
The term "acetaminophen", as used herein, shall have the art accepted meaning and refers to N-(4- Hydroxyphenyl) acetamide and ' -hydroxyacetanilide. The compound is claimed in U.S. Patent No. 2,998,450 and is known to the skilled artisan.
The term "central alpha-adrenergic active compounds", as used herein, represents a compound having central alpha-adrenergic receptor activity. The most preferred central alpha-adrenergic active compound is clonidine or a pharmaceutically acceptable salt thereof having the chemical name: 2- (2, 6-dichlorophenylamino) -2- imidazoline. Clonidine is known to be useful for treating hypertension. see Physicians' Desk Reference, 45th Ed. (1991) p. 673.
The term "opioid", as used herein, represents opioid analgesics and antagonists including natural opioid analgesics, synthetic opioid analgesics, opioid antagonists and opioid agonist-antagonists. Preferred an opioid compounds are selected from the group consisting of morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton's cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine. More preferred opioid compounds are selected from the group consisting of codeine, nabuphine, naloxone, and naltrexone.
Preferred an opioid compounds are morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton's cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine.
Especially preferred opioid compounds are selected from the group consisting of hydromorphone, hydrocodone, meperidone, buprenorphine, butorphenol, nalbuphine, pentazocine, oxymorphine, oxycodone, levorphanol, fentanyl, and alphaprodine.
Particularly preferred opioid compounds are selected from the group consisting of propoxyphene, methadone, morphine, hydrocodone, hydromorphine, and codeine. The especially particularly preferred opioid compounds are selected from morphine and codeine.
As used herein, the phrase "one or more" most preferredly refers to one; however, two, three, or more may be used.
We have discovered that a group of compounds having muscarinic cholinergic activity can be particular useful for treating pain when used in combination with non-steroidal antiinflammatory agents (NSAIDS) . More specifically, the invention provides a method of treating pain in humans using a specified azacyclic, azabicyclic or tetrahydropyridine compounds (collectively referred to herein as "selected muscarinic compounds") in combination with a NSAIDS to provide a synergistic effect. The Selected Muscarinic
Compounds are believed to be active based on activity at muscarinic cholinergic receptors; however, the present invention is in no way limited by the mechanism of action. There are many NSAIDS known in the literature and to the skilled artisan.
We have discovered that a group of compounds having muscarinic cholinergic activity can be particular useful for treating pain when used in combination with acetaminophen. More specifically, the invention provides a method of treating pain in humans using a specified Selected Muscarinic Compounds in combination with acetaminophen to provide a synergistic effect.
Further, we have discovered that a group of compounds having muscarinic cholinergic activity can be particularly useful for treating pain when used in combination with central alpha-adrenergic active compounds. More specifically, the invention provides a method of treating pain in humans using Selected Muscarinic Compounds in combination with a central alpha-adrenergic active compound to provide a synergistic effect.
Oral combinations of aspirin with codeine or other narcotic analgesics are known to provide additive analgesic effects in man. The Pharmacological Basis of Therapeutics, 5th edition, Macmillan Publishing Co., 1975, pp 325-358.
In the composition of this invention a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof and NSAIDS compound are combined in a weight ratio of Compound to NSAIDS of from about 1 to about 1000.
A preferred composition is a weight ratio of Compound to NSAIDS of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
In the composition of this invention a Compound of Formula or Formula II and acetaminophen are combined in a weight ratio of Formula I or Formula II to acetaminophen of from about 1 to about 1000.
A preferred composition is a weight ratio of Formula I or Formula II to acetaminophen of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
The compounds of Formula I and Formula II are effective over a wide dosage range; however, it is desirable to administer a dosage that is as low as possible. The amount of NSAIDS present in the composition is adjusted as described above in ratio to the Formula I or Formula II dosage. The amount of acetaminophen present in the composition is adjusted as described above in ratio to the Formula I or Formula II dosage. For example, dosages per day of the Formula II compounds will normally fall within the range of about 0.005 to about 100 mg/kg of body weight and the acetaminophen in the composition would be from 3 to 1000 times this amount. For example, dosages per day of the Formula I compounds will normally fall within the range of about 0.005 to about 100 mg/kg of body weight and the NSAIDS in the composition would be from 3 to 1000 times this amount.
In the composition of thiε invention a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt thereof and one or more opioid compounds are combined in a weight ratio of Compound to opioid compound of from about 1 to about 1000.
A preferred composition is a weight ratio of Compound to opioid compound of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
The Compounds are effective over a wide dosage range; however, it is desirable to administer a dosage that is as low as possible. The amount of opioid compound present in the composition is adjusted as described above in ratio to the Compound dosage. For example, dosages per day of the Formula I compounds will normally fall within the range of about 0.005 to about 100 mg/kg of body weight and the opioid compound in the composition would be from 3 to 1000 times this amount.
However, for each composition claimed herein, it will be understood that the amount of the Compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of Compound to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. While the present compounds are preferably administered orally to humans susceptible to or suffering from pain, the compoundε may also be administered by a variety of other routes such as the transdermal, parenterally, subcutaneous, intranasal, intramuscular and intravenous routes. Such formulations may be designed to provide delayed or controlled release using formulation techniques which are known in the art .
Transdermal formulations containing the composition claimed herein most preferably deliver the active substances in an effective amount for from about three days to about seven days. However, for chronic pain such as arthritis or cancer pain, a transdermal delivery of from about three days to up to about two weeks is desirable. Alternatively, it may be preferred to deliver the claimed compositions transdermally in an effective amount for from about one day to about three days .
As used herein the term "treating" includes prophylaxis of a physical and/or mental condition or amelioration or elimination of the developed physical and/or mental condition once it has been established or alleviation of the characteristic symptoms of such condition.
The compounds of Formula I and Formula II employed in the invention are not believed to act via the GABA/benzodiazepine, 5HT1A, or Dl receptor systems in humans. Rather, the activity of the present Formula I and Formula II compounds as analgesic agents is believed to be based upon modulation of muscarinic cholinergic receptors. However, the mechanism by which the present compounds function is not necessarily the mechanism stated supra . , and the present invention is not limited by any mode of operation.
The compounds of Formula I and Formula II are described in Sauerberg et al . in U.S. Patents 5,043,345, 5,041,455 and 5,260,314 (collectively herein "Sauerberg Patents"), each of which is herein incorporated by reference. The Sauerberg Patents teach the artisan how to make the compounds of Formula I and Formula II used herein for the claimed analgesic composition. Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically-acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science. 66, 2 (1977) which are known to the skilled artisan. The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
The route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, depot, subcutaneous, intravenous, intramuscular or intranasal, the oral route being preferred.
The dosage administered will, of course, vary depending on known factors such as the pharmacodynamic characteristics of the particular agent, and it smode and route of administration; age, health, and weight of the recipient; nature and extent of the symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired. Usually, the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 100 mg/kg of body weight Formula I or Formula II compound and from about 0.6 to about 200 mg/kg of NSAIDS. Compositions suitable for internal administration contain from about one half (0.5) milligrams to about 600 milligrams of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of from about 0.5% to about 95% by weight based on the total weight of the composition. For compositions containing acetaminophen, usually, the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 100 mg/kg of body weight Formula II compound and from about 0.6 to about 200 mg/kg of acetaminophen.
Typical compositions include a compound of Formula I or Formula II or a pharmaceutically acceptable acid addition salt thereof and one or more NSAIDSs, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves aε a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art. Typical compositions include a compound of Formula I or Formula II or a pharmaceutically acceptable acid addition salt thereof and acetaminophen, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used, as described above.
A preferred composition is a weight ratio of Compound to central alpha-adrenergic active compound of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
The compounds of Formula I and Formula II are effective over a wide dosage range; however, it is desirable to administer a dosage that is as low as possible. The amount of central alpha-adrenergic active compound present in the composition is adjusted as described above in ratio to the Formula I or Formula II dosage. For example, dosages per day of the Formula I compounds will normally fall within the range of about 0.005 to about 100 mg/kg of body weight and the central alpha-adrenergic active compound in the composition would be from 3 to 1000 times this amount.
Usually, the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 100 mg/kg of body weight Formula I or Formula II compound and from about 0.6 to about 200 mg/kg of central alpha-adrenergic active compound.
Typical compositions include a compound of formula I or Formula II or a pharmaceutically acceptable acid addition salt thereof; and one or more central alpha- adrenergic active compounds, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container. In making the compositions, conventional techniqueε for the preparation of pharmaceutical compoεitionε may be used.
The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic preεsure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.
For parenteral application, particularly suitable are injectable solutions or suspenεionε, preferably aqueous solutions with the active compound disεolved in polyhydroxylated castor oil.
Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.
Generally, the Formula I or Formula II compounds are dispensed in unit form comprising from about 0.1 to about 100 mg in a pharmaceutically acceptable carrier per unit dosage.
The compositions of this invention may be suitable for administration to an animal. Such animals include both domestic animals, for example livestock, laboratory animals, and household pets, and non-domestic animals such as wildlife. More preferredly, the animal is a vertebrate. Most preferredly, a compound of this invention shall be administered to a mammal. It is especially preferred that the animal is a domestic mammal or a human. The most preferred mammal is a human. For such purposes, a compound of this invention may be administered as a feed additive.
The following models and assays are useful for illustrating the effectiveness of the compositions claimed herein.
Nocieeptive pain model:
Acetic acid-induced writhing: A standard procedure for detecting and comparing the analgesic activity of different classes of analgesic drugs for which there is a good correlation with human analgesic activity is the prevention of acetic acid-induced writhing in mice. Mice, are subcutaneously administered various doses of the claimed composition and are injected injected intraperitoneally with acetic acid (0.5% solution, 10 ml/kg) 5 min prior to a designated observation period. For scoring purposes a "writhe" is indicated by whole body stretching or contraction of the abdomen during the observation period beginning 5 min after receiving the acetic acid. Inhibition of writhing behavior is demonstrative of analgesic activity.
See, Haubrich, D.R., Ward, S.J., Baizman, E. , Bell, M.R., Bradford, J., Ferrari, R., Miller, M. , Perrone, M. , Pierson, A.K., Saelens, J.K. and Luttinger, D. : Pharmacology of pravadoline: a new analgesic agent. The Journal of Pharmacology and Experimental Therapeutics 255 (1990) 511-522.
qeyropathic pain iwpdel;
Sciatic nerve ligation model: Rats are anesthetized and a nerve ligation procedure performed. The common sciatic nerve is exposed and 4 ligatures tied loosely around it with about 1 mm spacing. One day to 10 weeks after surgery, the nocieeptive testing is performed. Responses to noxious heat are determined by placing the rats in a chamber with a clear glass floor and aiming at the plantar surface of the affected foot a radiant heat source from beneath the floor. Increased latency to withdraw the hindpaw is demonstrative of analgesic activity. Responses to normally innocuous mechanical stimuli is determined by placing the rats in a chamber with a screen floor and stimulating the plantar surface of the hind paw with graduated von Frey hairs which are calibrated by the grams of force required to bend them. Rats with sciatic nerve ligation respond to lower grams of mechanical stimulation by reflexive withdrawal of the foot than unoperated rats. This response to stimuli which are normally innocuous is termed allodynia. Increases in the grams of mechanical force required to produce foot withdrawal is demonstrative of antiallodynic activity. See, Bennett, G.J. and Xie, Y.-K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107. See also, Lee, Y.-W., Chaplan, S.R. and Yaksh, T.L. :
Systemic and supraspinal, but not spinal, opiates suppreεs allodynia in a rat neuropathic pain model. Neuroci Lett 186 (1995) 111-114. Formalin paw test: Rats are anesthetized and when there is a loss of spontaneous movement the rats are injected subcutaneously in the dorεal εurface of the hindpaw with 50 ul of 5% formalin solution using a 30 gauge needle. Rats are then individually placed in an open Plexiglas chamber for observation, and within a maximum interval of 1 to 2 min, the animal displays recovery from anesthesia with spontaneous activity and normal motor function. Pain behavior is quantified by periodically counting the incidents of spontaneous flinching/shaking of the injected paw. The flinches are counted for 1-min periods at 1- to 2-, 5- to 6- and 5min intervals during the interval from 10 to 60 min. Inhibition of the pain behavior is demonstrative of an analgesic activity.
See, Malmberg, A.B. and Yaksh, T.L. : Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. The Journal of Pharmacology and Experimental Therapeutics 263 (1992) 136-146. Infla matorv pain model:
Brewer's yeast-induced hyperalgesia (Randall-Selitto Test) : To assess nocieeptive threshold in rats, ascending pressure is applied gradually to the paw with a motor driven weight of a Ugo Basile Analgesy Meter. Rats respond to the pressure by either pulling free of the device, struggling or vocalizing. Hyperalgesia is induced by a hind paw subplantar injection of 0.1 ml of 1% suspension of brewer's yeast in 0.9% saline. The composition of this invention is administered at varying times ( 0 - 4 hr) after injection of brewer's yeast and pressure threshold for the inflamed paw again determined at varying times. Increases in the pressure which produces a behavioral response is demonstrative of analgesic activity. See, Haubrich, D.R., Ward, S.J., Baizman, E. , Bell, M.R. , Bradford, J., Ferrari, R., Miller, M. , Perrone, M. , Pierson, A.K. , Saelens, J.K. and Luttinger, D. : Pharmacology of pravadoline: a new analgesic agent. The Journal of Pharmacology and Experimental Therapeutics 255 (1990) 511-522.
Utility Test Methods The unexpectedly enhanced analgesic activity of the composition of the invention is evidenced by tests intially conducted on mice. Male mice are fasted for 16-22 hours and weighed. Mice weighing from about 18-22 grams at the time of testing are used for the following studies. All mice are dosed sequentially by the oral route with suspensions of a composition of this invention. Doses are coded using a code unknown to the observer.
A stock suspension of the test composition is prepared by mixing the active ingredients with about 40 mL of an aqueous vehicle containing about 2% Tween 80 (R) , a pharmacological dispersant and containing 100% polysorbate 80, and 1% by weight Methocel (R) MC powder, and containing 100% methylcellulose, in distilled water. The mixture may be sonicated for about 10 to about 15 seconds using an ultrasound sytem. All dosing suspensions are prepared by dilution of the stock suspension with Methocel/Tween 80. All suspensions are used within two hours of preparation.
Mouse Writhing Test
An accepted standard for detecting and comparing the analgesic activity of different classes of analgesic compounds for which there is a good correlation with human analgesic activity is the prevention of phenyl-p- benzoquinone induced writhing in mice. [H. Blumberg et al . Proc. Soc. Exp. biol. Med., 118, 763-766 (1965)] .
Mice, treated with various doses of compound of Formula I or Formula II, composition or vehicle are injected intraperitoneally with a standard challenge dose of phenyl-p-benzoquinone 5 minutes prior to a designated observation period. The pheyl-p-benzoquinone is prepared as about 0.1 mg/ml solution in about 5% by volume of ethanol in water. The writhing dose is 1.25 mg/kg injected at a volume of about 0.25ml/10g. For scoring purposes a "writhe" is indicated by whole body stretching or contracting of the abdomen during an observation period beginning about five minutes after the phenyl-p- benzoquinone dose.
All ED50 values and their 95% confidence limits are determined using accepted numerical methodε. For example, see W.F. Thompson, Bacteriological Rev.. 11, 115-
145 (1947) . The interaction of the dosages on phenyl-p- benzoquinone induced writhing in mice is demonstrated by the Loewe isobologram (S. Loewe, Pharm. Rev. 9, 237-242 (1957) .
The solid line connecting the ED50 dosages of Formula I or Formula II (alone) and classical analgesic as claimed herein (alone) represents the "ED50 addition line" which indicates the expected location of the ED50's for Formula I or Formula II and classical analagesic combinations if simple additivity were to describe their combined effects. The 95% confidence range for the ED50 addition line is shown by the area between the broken lines above and below the ED50 addition line.
According to Loewe' s isobolic theory, if the analgesic effects are simply additive to one another, then the expected location of the ED50's of the Formula I or
Formula II and classical analgesic component of each fixed dosage ratio would be contained within or overlap the region of the ED50 addition line. Combination ED50 ' s located significantly below the ED50 addition line would represent unexpectedly enhanced analgesic activity and combination ED50 ' s located above the line would represent unexpected diminished analgesic effect.
One method to establish the significance of such unexpected enhanced or diminished activity is to calculate the best fitting polynomial regression line to the observed ED50's using standard mathematical techniques.
Such experiments demonstrate that compositions comprised of a compound of Formula I or Formula II and one or more classical analgesics provides a statistically significant synergistic analgesic effect.
Preferred compounds of Formula I for use in the analesic compositions are selected from the following:
3-CHLORO-3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[2.2.2]OCTANE;
3-(3-CHLORO-l,2,5-THIADIAZOL-4-YL)-3-HYDROXY-l- AZABICYCLO[2.2.2]OCTANE;
3-METHOXY-3- (3-METHOXY-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO[2.2.2]OCTANE;
3- (3-METHOXY-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO[2.2.2]OCT-2■ ENE; 3- (3-HEXYLOXY-1,2,5-THIADIAZ0 -4-YD-1-AZABICYCLO[2.2.2]0C - 2-ENE;
3-HEXYL0XY-3- (3-HEXYLOXY-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- [2.2.2JOCTANE;
3- (3-HEXYLOXY-l,2,5-THIADIAZOL-4-YL) -3-HYDROXY-1- AZABICYCLO[2.2.2]OCTANE;
3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO[2.2.2]OCTANE;:
3- (3-ETHOXY-1,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO [2.2.2]OCTANE;
3- (3-PROPOXY-l, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
3- {3-BUTOXY-1,2, 5-THIADIAZOL-4-YL)-l-AZABICYCLO 12.2.2]OCTANE;
3- (3-PENTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- [2.2.2]OCTANE;
3- (3-ETHOXY-l,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO [2.2.2]OCTANE;
3- (3-HEXYLTHIO-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
3- (3- (3-PHENYLPROPYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
3- (3-HEXYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
3- (3- {4-CYANOBENZYLTHIO) -1, 2 , 5-THIADIAZOL-4-YL) -1- AZABICYC O[2.2.2]OCTANE;
EXO-6- (3-CHLORO-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE; END0-6- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-HEXYLTHIO-l,2,5-THIADIAZOL-4-YL)-l- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-(5-HEXENYLTHIO)-l,2,5-THIADIAZOL-4-YL)-l- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-BUTYLTHIO-l, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-PENTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-ETHYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3- (3-PHENYLPROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1-
AZABICYCLO[3.2.1]OCTANE;
Particularly preferred compounds of Formula I include:
3- (3-HEXYLTHIO-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
3- (3- (3-PHENYLPROPYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO (2.2.2)OCTANE
(EXO(+-) ) -6- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- (3.2.1)OCTANE
3- (3-ETHOXY-1,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO(2.2.2)OCTANE
3- (3-PROPOXY-1,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO (2.2.2)OCTANE 3-(3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YL)-l- AZABICYCLO(2.2.2)OCTANE
3- (3-PENTYLTHIO-l, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO(2.2.2)OCTANE
ENDO (+-) -6- (3-ETHYLTHIO-1,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO- (3.2.1)OCTANE
ENDO(+-) -6- (3-BUTYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- (3.2.1)OCTANE
EXO -) -6- (3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO- (3.2.1)OCTANE
3- (3- (BUTOXY-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO(2.2.2)OCTANE
EXO-3- (3-PROPYLTHIO-l, 2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- (2.2.1)HEPTANE
EXO-3- (3-BUTYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO(2.2.1) -HEPTANE
ENDO-3- (3-BUTYLTHIO-l, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO(2.2.1) -HEPTANE
3- (3-ETHYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO(2.2.2)OCTANE
3- (3-PROPYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO(2.2.2)OCTANE
4-CHLORO-3- (3-PROPYLOXY-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- (3.3.DNON-2-ENE
3- (3-ISOPENTYLOXY-l,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO (2.2.2) - OCTANE
ENDO ( +- ) 3 - ( 3-PROPYLTHIO-1,2,5-THIADIAZOL-4- L) -1-AZABICYCLO-
(3.2.1)OCTANE
EXO(+-)3- (3-PROPYLTHIO-1,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO-
(3.2.1)OCTANE
-)3- (3-BUTYLTHIO-1,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO(2.2.2)- OCTANE
(+)3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL- -YL) -1-AZABICYCLO (2.2.2) - OCTANE
3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO(2.2.2)OCTANE
(EXO (+-) ) -6- (3-CHLORO-1, 2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- (3.2.1)OCTANE
3- (3-ETHOXY-l,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO (2.2.2)OCTANE
3- (3-PROPOXY-1,2, 5-THIADIAZOL- -YL) -1-AZABICYCLO(2.2.2)OCTANE
3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO (2.2.2JOCTANE
3-(3-PENTYLTHIO-l,2,5-THIADIAZOL-4-YL)-l- AZABICYCLO(2.2.2)OCTANE
ENDO(+-) -6- (3-ETHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- (3.2.1)OCTANE
ENDO(+-) -6- (3-BUTYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- (3.2.1)OCTANE
EXO(+-)-6- (3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YL)-l-AZABICYCLO- (3.2.1JOCTANE 3- (3- (BUTOXY-1,2,5-THIADIAZOL-4-Y ) -1-AZABICYCLO(2.2.2)OCTANE
EXO-3- (3-PROPYLTHIO-l, 2, 5-THIADIAZOL-4-YL) -1-
AZABICYCLO (2.2.1)-
HEPTANE
3- (3-ETHYLTHIO-1, 2, 5-THIADIAZOL- -YL) -1- AZABICYCLO (2.2.2)OCTANE
EXO-3- (3-BUTYLTHIO-1, 2 , 5-THIADIAZOL- -YL) -1- AZABICYCLO(2.2.1) -HEPTANE
ENDO-3- (3-BUTYLTHIO-1,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO(2.2.1) -HEPTANE
3- (3-ETHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO(2.2.2)OCTANE
3- (3-PROPYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO (2.2.2)OCTANE
4-CHLORO-3- (3-PROPYLOXY-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO-
(3.3.DNON-2-ENE
3- (3-ISOPENTYLOXY-l, 2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO-
(2.2.2)OCTANE
ENDO -) 3- (3-PROPYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- (3.2.DOCTANE
BIS-1, 4- (3- (1-METHYL-l, 2, 5, 6-TETRAHYDROPYRIDIN-3-YL) -1,2,5- THIADIAZOL-4-YL)BUTANEDITHIOL
EXO(+-)3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- (3.2.1)OCTANE (-)3-(3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO- (2.2.2) OCTANE
(+) 3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- (2.2.2. )OCTANE; AND a pharmaceutically acceptable salt or solvate thereof.
More preferred compounds include the following: 3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO(2.2.2)OCTANE
3- (3-PENTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO (2.2.2)OCTANE
ENDO(±) -6- (3-ETHYLTHIO-l,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO- (3.2.1)OCTANE
ENDO(±) -6- (3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YL)-l-AZABICYCLO-
(3.2.1)OCTANE
EXO (±)-6- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO-
(3.2.1)OCTANE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO(2.2.2)OCTANE; or a pharmaceutically acceptable salt or solvate thereof.
The most especially preferred compound of Formula I is 3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL- -YL) -1- AZABICYCLO [2.2.2]OCTANE; or a pharmaceutically acceptable salt or solvate thereof.
Preferred compounds of Formula II for the analgesic composition are selected from the following:
3- ( -METHOXY-1,2, 5-THIADIAZOL- -YL) -1,2,5, 6-TETRAHYDRO-l- METHYLPYRIDINE 3- (3-ETHOXY-l,2, -THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPOXY-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-BUTOXY-1,2, 5-THIADIAZOL-4-YL) 1,2,5, 6-TETTRAHYDRO-l- METHYLPYRIDINE
3- (3-ISOPROPOXY-1,2, 5-THIADIAZOL-4-YL) -1, 2 , 5, 6-TETRAHYDRO-1• METHYLPYRIDINE
3- (3-CYCLOPROPYLMETHOXY-l,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-PENTOXY-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-l- METHYLPYRIDINE
3-(3-ISOBUTOXY-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3- (3-BUTENOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (BUT-2-YNOXY)-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (3-METHYLBUTOXY) -1,2,5-THIADIAZOL-4-YL) -1, 2 , 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (PROP-2-YNOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3-BENZYLOXY-1,2, 5-THIADIAZOL-4-YL) -1, 2 , 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CHLORO-1,2, 5-THIADIAZOL- -YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CHLORO-1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDROPYRIDINE
3- (3-BUTOXY-1,2,5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDROPYRIDINE
3- (3-ETHOXY-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- ETHYLPYRIDINE
3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- ETHYLPYRIDINE
3- (3-METHOXYETHOXY-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3-HEPTYLOXY-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3-(3-PENTYNYLOXY) -1,2, 5-THIADIAZOL- -YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-PENTENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-PROPENYLOXY)-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-OCTYLOXY-l, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (3-HEXYNYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3- (3-BUTENYL-2-OXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYL-PYRIDINE
3- (3- (4-HEXENYLOXY(-1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
TRANS-3- (3- (3-HEXENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3- (3- (2-PENTENYLOXY)-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3- (3- (2-HEXENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (5-HEXENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3- (3- (3-HEXENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2, 4, 5- TETRAHYDRO-1-METHYLPYRIDINE
TRANS-3- (3- (2-HEXENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-METHYLPIPERIDINO-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-MORPHOLINO-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3-DIMETHYLAMINO-1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3-HEXYLAMINO-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE 3- (3-HEXYLOXY-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- DEUTEROMETHYLPYRIDINE
1,2,5, 6-TETRAHYDRO-3- (3-HEXYL0XY-1, 2, 5-THIADIAZOL-4- YL) PYRIDINE
3- (3- (2- (2-METHOXYETHOXY) -ETHOXY) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-l-METHYLPYRIDINE
3- (3- (3-ETHOXY-1-PROPOXY) -1, 2, 5-THIADIAZOL- -YL) -1,2, 5, 6, - TETRAHYDRO-1-METHYLPYRIDINE
3- (2-ETHOXYETHOXY) -1,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (2-BUTOXYETHOXY) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2- (2-BUTOXYETHOXY) -ETHOXY) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2- (2-ETHOXYETHOXY) -ETHOXY) -1, 2, 5-THIADIAZOL-4-YL) - 1,2 , 5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-METHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PENTYL-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE 3- (3-HEXYLTHI0-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PENTYLTHIO-l, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-ETHYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-OCTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYL-1,2, 5-THIADIAZOL-4-YL)-l,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-HEPTYL-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (5-HEXENYL) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-OCTYL-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYPYRIDINE
3- (3- (2-METHYL) -BUTYL-1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-METHYLCYCLOPROPYL-1,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-CYCLOPENTYLTHIO-1,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (l-ETHYLTHIO-2-METHOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3- (3-CHLORO-1-PROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-METHOXYETHOXY) -ETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-CYANO-1-PROPYLTHIO) -1, 2, 5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BENZYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (2-ETHOXY-l-ETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-PENTYNYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2- (2-ETHOXYMETHOXY) -ETHYLTHIO) -1,2, 5-THIADIAZOL- -YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (5-CYANO-l-PENTYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1, 2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-(3-PHENYL-l-PROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-PHENOXYETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1, 2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-(4-CYANOBUTYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-(2-ETHYLBUTYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3-CYCLOHEXYLMETHYLTHIO-1,2,5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (8-HYDROXYOCTYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (7-OCTENYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2 , 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-CYCLOPROPYLMETHYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3 (3-CYCLOPROPYLMETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-BUTENYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-PENTENYLTHIO)-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (4-ISOHEXYLOXY-1,2, 5-THIADIAZOL-3-Y ) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
l-METHYL-l,2,5,6-TETRAHYDRO-3-( (4-CYCLOPENTYLPROPYL)OXY) - 1,2, 5-THIADIAZOL-3-YL) PYRIDINE
1-METHYL-1, 2, 5, 6-TETRAHYDRO-3- (4-ISOHEPTYLOXY-l, 2, 5- THIADIAZOL-3-YL) PYRIDINE
l-METHYL-1,2,5, 6-TETRAHYDRO-3- (4( (2-CYCLOHEXYLETHYL)OXY) - 1,2, 5-THIADIAZOL-3-YL) PYRIDINE
1, 2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (1-METHYLHEXLOXY) -1,2,5- THIADIAZOL-3-YL) PYRIDINE 3- (4- (1-ETHYLPENTYLOXY) -1, 2, 5-THIADIAZOL-3-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (4- (1-ETHYLBUTOXY) -1,2, 5-THIADIAZOL-3-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
1,2,5,6-TETRAHYDRO-1-METHYL-3- (4- (1-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-)YL)PYRIDINE
l-METHYL-3- (4- (5-HEXENYLOXY) -1,2, 5-THIADIAZOL-3-YL) -1,2,5,6- TETRAHYDROPYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLBUTOXY) -1,2,5- THIADIAZOL-3-YL)PYRIDINE
1,2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-YL)PYRIDINE
1,2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (2,2,2-TRIFLUOROETHOXY) - 1,2, 5-THIADIAZOL-3-YL) PYRIDINE
1-METHYL-1,2, 5, 6-TETRAHYDRO-3- (4- (3-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-YL)PYRIDINE
3- (3- (3-METHYL-2-BUTENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDO-1-METHYLPYRIDINE
3- (3-ISOBUTOXY-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLBUTOXY) -1,2,5- THIADIAZOL-3-YL) PYRIDINE
3- (3- (3-HYDROXYPROPOXY) -1,2, 5-THIADIAZOL- -YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE (+-) 1, 6-DIMETHYL-3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDROPYRIDINE
3- (3- (3-PHENYL-ETHYLTHIO) -1, 2,5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
BIS-1, 4- (3- (l-METHYL-1,2, 5, 6-TETRAHYDROPYRIDIN-3-YL) -1,2,5- THIADIAZOL-4-YL)BUTANEDITHIOL
3- (3- (4, 4, 4-TRIFLUOROBUTOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5- THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3,3,3-TRIFLUOROPROPYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1, 1- DIMETHYLPYRIDINIUM IODIDE
(+-) 1, 6-DIMETHYL-3- (3-BUTYLTHIO-1, 2 , 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDROPYRIDINE
(+-) 1, 6-DIMETHYL-3- (3-BUTOXY-1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDROPYRIDINE
3- (3- (3-METHYL-2-BUTENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDO-1-METHYL PYRIDINE
3- (3-ISOBUTOXY-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE 1,2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLBUTOXY)-1, 2 , 5- THIADIAZO -3-YL)PYRIDINE
3- (3- (3-HYDROXYPROPOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6- TETRAHYDRO-1-METHYLPYRIDINE
(+-) 1, 6-DIMETHYL-3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDROPYRIDINE
3- (3- (3-PHENYL-ETHYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
BIS-1,4- (3- (l-METHYL-l,2,5,6-TETRAHYDROPYRIDIN-3-YL) -1,2,5- THIADIAZOL-4-YDBUTANEDITHIOL
3- (3- (4,4,4-TRIFLUOROBUTOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3,3, 3-TRIFLUOROPROPYLTHIO)-l,2,5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-PROPYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL- -YL) -1,2,5,6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1, 1- DIMETHYLPYRIDINIUM IODIDE
(+-)l,6-DIMETHYL-3-(3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YL) - 1,2, 5, 6-TETRAHYDROPYRIDINE (+-)l,6-DIMETHYL-3- (3-BUTOXY-l, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE; or a pharmaceutically acceptable salt thereof.
Especially preferred compounds include the following:
3- (3-BUTYLTHIO-1,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-METHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PENTYL-1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-HEXYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PENTYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-ETHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-OCTYLTHIO-1,2, 5-THIADIAZOL-4-YD-1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-METHOXY-1,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3-(3-ETHOXY-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE 3- (3-PROPOXY-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-BUTOXY-1, 2, 5-THIADIAZOL-4-YL) 1,2,5, 6-TETTRAHYDRO-l- METHYLPYRIDINE
3- (3-ISOPROPOXY-1,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CYCLOPROPYLMETHOXY-1,2,5-THI DIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-PENTOXY-l,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-ISOBUTOXY-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (3-BUTENOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3-(3-(BUT-2-YNOXY)-l,2,5-THIADIAZOL-4-YL) -1,2, 5 , 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (3-METHYLBUTOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-HEXYLOXY-l,2,5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (PROP-2-YNOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6-
TETRAHYDRO-1-METHYLPYRIDINE; or a pharmaceutically acceptable salt or solvate thereof.
Compound which are particularly preferred include:
3- (3-HEXYLOXY-1,2, 5-THIADIAZOL-4-YD-1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE; and 3- (3-HEXYLTHIO-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l-
METHYLPYRIDINE; or a pharmaceutically acceptable salt or solvate thereof.

Claims

C l a ims
1. A composition for treating pain comprising an analgesic dose of a Compound selected from the group consiεting of formula I
Figure imgf000046_0001
wherein
X is oxygen or sulphur;
R is hydrogen, amino, halogen, -CHO, -NO2, -OR4, -SR4, -SOR4, -SO2R4, C3-7-cycloalkyl, C4-8- (cycloalkylalkyi) , -Z-C3-7- cycloalkyl, and -Z-C4-.8- (cycloalkylalkyi) wherein R4 is straight or branched Cι-15-alkyl, straight or branched C2-15- alkenyl, straight or branched C2-i5-alkynyl, each of which is optionally substituted with one or more halogens, -CF3, -CN, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, Cι-4-alkyl, Cι-4-alkoxy, -OCF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, Cι_4-alkyl, Cι-4-alkoxy, -OCF3, -CONH2 or -CSNH2; or R iε -OR5Y, -SR5Y, -OR5ZY, -SR5ZY, -0-R4-Z- R5 or -S-R -Z-R5 wherein Z is oxygen or sulphur, R5 is straight or branched C -15-alkynyl, and Y is a 5 or 6 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched Ci-g-alkyl, phenyl or benzyl, or which heterocyclic group is optionally fused with a phenyl group; and G is selected from one of the following azabicyclic rings
Figure imgf000047_0001
wherein the thiadiazole or oxadiazole ring can be attached at any carbon atom of the azabicyclic ring; R1 and R2 may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C1-5- alkyl, straight or branched C2-5 alkenyl, straight or branched C2-5-alkynyl, straight or branched Cι_ιo-alkoxy, straight or branched Cι-5-alkyl substituted with -OH, OR4, halogen, -NH2 or carboxy; R3 is H, straight or branched Cι_ 5-alkyl, straight or branched C2-5-alkenyl or straight or branched C2-5-alkynyl; n is 0, 1 or 2; m is 0, 1 or 2; p is
0, 1 or 2 ; q is 1 or 2; and is a single or double bond; or a pharmaceutically acceptable salt or solvate thereof; and
Formula II
Figure imgf000047_0002
wherein
Z1' is oxygen or sulphur; R' is hydrogen, halogen, amino, -NHCO-R2', C3-7-cycloalkyl, C4-10*" (cycloalkylalkyi) , -Z2' -C3-7-cycloalkyl optionally substituted with Cι-6-alkyl, -Z2' -C4-10- (cycloalkylalkyi) , -Z2' -C4--10- (cycloalkenylalkyl) , -Z2'-C4-ιo- (methylenecycloalkyl-alkyl) ,
-NH-R2', -NR2'R3', -NH-OR2' , phenyl, phenoxy, benzoyl, benzyloxycarbonyl, tetrahydronaphtyl, indenyl, X', R2' , -Z 'R2', -SOR2', -S02R2', -Z2,-R2'-Z3'-R3', -Z 2 *-R '-Z3 '-R3 ' -Z4' - R4', -Z2'-R 'CO-R3', -Z2'-R2'-Cθ2-R3' , Z2'-R2'-θ2C-R3' , -Z2' -R2' -CONH-R3' , -Z2'-R2'- NHCOR3' ,
-Z2'-R2'-X', -Z2'-R2'-Z3'-X' , wherein Z2' , Z3 ' , and Z4 ' independently are oxygen or sulphur, and R2 ' , R3 ' and R ' independently are straight or branched Cι-15-alkyl, straight or branched C2-i5~alkenyl, straight or branched C2-15-alkynyl, each of which is optionally substituted with halogen(s), -OH, -CN, -CF3, -SH, -COOH, -NH-R2', -NR2'R3', Ci-6alkyl ester, one or two phenyl, phenoxy, benzoyl or benzyloxycarbonyl wherein each aromatic group is optionally substituted with one or two halogen, -CN, Cι-4-alkyl or
Cι-4-alkoxy, and X' is a 5 or 6 membered heterocyclic group containing one to four N, O or S atom(ε) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched C1-6- alkyl, phenyl, benzyl or pyridine, or a carbon atom in the heterocyclic group together with an oxygen atom form a carbonyl group, or which heterocyclic group is optionally fused with a phenyl group; and R5' and R6' may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C1-5- alkyl, straight or branched C2-5-alkenyl, straight or branched C2-5-alkynyl, εtraight or branched Cι-10-alkoxy, straight or branched Ci-5-alkyl substituted with -OH, -OH, halogen, - H2 or carboxy; R1' is hydrogen, straight or branched Ci-5-alkyl, straight or branched C2-5~alkenyl or straight or branched C2-5-alkynyl; or a pharmaceutically acceptable salt or solvate thereof; and a nonsteroidal anti-inflammatory drug in a weight ratio of Compound to nonsteroidal anti-inflammatory drug (NSAIDS) of from about 1 to about 1000.
2. A composition as claimed by Claim 1 wherein the Compound is of the formula I
Figure imgf000049_0001
wherein
X is oxygen or sulphur;
R is hydrogen, amino, halogen, -CHO, -NO2, -OR4, -SR4, -SOR4, -SO2R4, C3_7-cycloalkyl, C4-8- (cycloalkylalkyi) , -Z-C3-7- cycloalkyl, and -Z-C4-8- (cycloalkylalkyi) wherein R4 is straight or branched Cι_i5-alkyl, straight or branched C2-15- alkenyl, straight or branched C2-i5-alkynyl, each of which is optionally substituted with one or more halogens, -CF3, -CN, phenyl or phenoxy wherein phenyl or phenoxy iε optionally εubεtituted with halogen, -CN, Cι_4-alkyl, Cι_4-alkoxy, -OCF3, -CONH2 or -CSNH2; or R iε phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, Cι-4-alkyl, Cι-4-alkoxy, -OCF3, -CONH2 or -CSNH2; or R is -OR5Y, -SR5Y, -OR5ZY, -SR5ZY, -0-R4-Z- R5 or -S-R4-Z-R5 wherein Z is oxygen or sulphur, R5 is straight or branched Cι-15-alkynyl, and Y is a 5 or 6 membered heterocyclic group containing one to four N, 0 or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched Cι_6-alkyl, phenyl or benzyl, or which heterocyclic group is optionally fused with a phenyl group; and G is selected from one of the following azabicyclic rings
Figure imgf000050_0001
wherein the thiadiazole or oxadiazole ring can be attached at any carbon atom of the azabicyclic ring; R1 and R2 may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C1-.5- alkyl, straight or branched C2-5 alkenyl, straight or branched C2-5-alkynyl, straight or branched Cι-10-alkoxy, straight or branched C _5-alkyl substituted with -OH, OR4, halogen, - H2 or carboxy; R3 is H, straight or branched Cι_ 5-alkyl, straight or branched C2-5-alkenyl or straight or branched C2-5~alkynyl; n is 0, 1 or 2; m iε 0, 1 or 2; p is 0, 1 or 2; q is 1 or 2; and is a single or double bond; or a pharmaceutically acceptable salt or solvate thereof; and a nonsteroidal anti-inflammatory drug in a weight ratio of Formula I to nonsteroidal anti-inflammatory drug (NSAIDS) of from about 1 to about 1000.
3. A composition of Claim 2 wherein X is S, G
Figure imgf000050_0002
wherein n is 1, p is 1 or 2 and m iε 1 or 2, R1 and R2 independently are hydrogen, methyl, hydroxy, halogen or amino; or a pharmaceutically acceptable salt or solvate thereof. 4. A composition of Claim 2 wherein X is S, G is
Figure imgf000051_0001
wherein n is 1, p is 1 or 2 and m is 1 or 2.
5. A composition according to Claim 2 wherein the compound of Formula I is selected from the group consisting of the following:
3-CHLORO-3- (3-CHLORO-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO[2.2.2]OCTANE;
3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -3-HYDROXY-1- AZABICYCLO[2.2.2]OCTANE;
3-METHOXY-3- (3-METHOXY-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO[2.2.2]OCTANE;
3- (3-METHOXY-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO[2.2.2]OCT-2- ENE;
3- (3-HEXYLOXY-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO[2.2.2]OCT- 2-ENE;
3-HEXYLOXY-3- (3-HEXYLOXY-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- [2.2.2]OCTANE;
3- (3-HEXYLOXY-1,2, 5-THIADIAZOL-4-YL) -3-HYDROXY-1- AZABICYCLO[2.2.2]OCTANE;
3-(3-CHLORO-l,2,5-THIADIAZOL-4-YL)-l-AZABICYCLO[2.2.2]OCTANE;
3- (3-ETHOXY-l,2,5-THIADIAZOL-4-YL)-l-AZABICYCL0[2.2.2]OCTANE; 3- (3-PROPOXY-l, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
3- (3-BUTOXY-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO [2.2.2]OCTANE;
3- (3-PENTYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- [2.2.2]OCTANE;
3- (3-ETHOXY-1,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO [2.2.2]OCTANE;
3- (3-HEXYLTHIO-l, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCL0 [2.2.2]OCTANE;
3- (3- (3-PHENYLPROPYLTHIO) -1,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
3- (3-HEXYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
3- (3-(4-CYANOBENZYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
EXO-6- (3-CHLORO-l,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-CHLORO-l,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-HEXYLTHIO-l, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3- (5-HEXENYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE; ENDO-6- (3-PENTYLTHIO-l,2,5-THIADIAZOL-4-YD -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-ETHYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3- (3-PHENYLPROPYLTHIO) -1,2, 5-THIADIAZOL- -YL) -1-
AZABICYCLO[3.2.1]OCTANE; or a pharmaceutically acceptable salt or solvate thereof.
6. A composition of Claim 2 wherein compound is 3- (3-BUTYLTHIO-l, 2, 5-THIADIAZOL-4-YL) -1-
AZABICYCL0[2.2.2]OCTANE; or a pharmaceutically acceptable salt or solvate thereof.
7. A composition of Claim 2 wherein the the non-steroidal antiinflammatory drug iε selected from the group consisting of salicylateε, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
8. A composition of Claim 7 wherein the non¬ steroidal antiinflammatory drugs is εelected from the group consisting of aspirin, ibuprofen, and naproxen.
9. A composition of Claim 2 wherein the weight ratio of a compound of Formula I to NSAIDS is from about ,1 to about 100.
10. A composition of Claim 7 wherein the weight ratio is from about 1 to about 30.
11. A composition of Claim 10 wherein the weight ratio is from about 1 to about 10. 12. A composition of Claim 11 wherein the weight ratio is from about 1 to about 3.
13. A composition of Claim 9 wherein the non- steroidal antiinflammatory drug is selected from the group consisting of aspirin and ibuprofen.
14. A composition of Claim 7 wherein the weight ratio of compound of Formula I to NSAIDS is from about 1 to about 100.
15. A composition of Claim 8 wherein the weight ratio of compound of Formula I to NSAIDS is from about 1 to about 100.
16. A method for treating pain comprising administering an analgesic dose of a composition comprising a compound of Formula I
Figure imgf000054_0001
wherein
X is oxygen or sulphur;
R is hydrogen, amino, halogen, -CHO, -NO2, -OR4, -SR4, -SOR4, -SO2R4, C3-7-cycloalkyl, C4-8- (cycloalkylalkyi) , -Z-C3.-7- cycloalkyl, and -Z-C4-8- (cycloalkylalkyi) wherein R4 iε straight or branched Cι_i5-alkyl, straight or branched C2-15- alkenyl, straight or branched C2-i5-alkynyl, each of which is optionally substituted with one or more halogens, -CF3, -CN, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, Cι-4-alkyl, Cχ-4-alkoxy, -OCF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, Cι_4~alkyl, Cι-4-alkoxy, -OCF3, -CONH2 or -CSNH2; or R is -0R5Y, -SR5Y, -OR5ZY, -SR5ZY, -0-R -Z- R5 or -S-R -Z-R5 wherein Z is oxygen or sulphur, R5 is straight or branched Cι_i5-alkynyl, and Y is a 5 or 6 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched Cχ_6-alkyl, phenyl or benzyl, or which heterocyclic group is optionally fuεed with a phenyl group; and G iε εelected from one of the following azabicyclic ringε
Figure imgf000055_0001
wherein the thiadiazole or oxadiazole ring can be attached at any carbon atom of the azabicyclic ring; R1 and R2 may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C1-.5- alkyl, straight or branched C2-5 alkenyl, straight or branched C2-5~alkynyl, straight or branched Cι-10-alkoxy, straight or branched Cι-5-alkyl substituted with -OH, OR4, halogen, -NH2 or carboxy; R3 is H, straight or branched Cι_ 5-alkyl, straight or branched C2-5-alkenyl or straight or branched C2-5~alkynyl; n is 0, 1 or 2; m is 0, 1 or 2; p is
0, 1 or 2; q is 1 or 2; and is a single or double bond; or a pharmaceutically acceptable salt or solvate thereof; and one or more NSAIDS in a weight ratio of Formula I to NSAIDS of from about 1 to about 1000.
17. A method of Claim 16 wherein the non¬ steroidal antiinflammatory drug is selected from the group consisting of salicylates, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac. 18. A method of Claim 17 wherein the non¬ steroidal antiinflammatory drug is selected from the group consisting of ibuprofen, and naproxen.
19. A method of Claim 16 wherein the weight ratio of a compound of Formula I to NSAIDS of from about 1 to about 100.
20. A method of Claim 19 wherein the weight ratio is from about 1 to about 30.
21. A method of Claim 20 wherein the weight ratio is from about 1 to about 10.
22. A method of Claim 21 wherein the weight ratio is from about 1 to about 3.
23. A method of Claim 22 wherein the compound of Formula I is 3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE; or a pharmaceutically acceptable salt or solvate thereof.
24. A method of Claim 22 wherein the composition is administered using a transdermal formulation.
25. A composition of Claim 1 wherein the compound is a compound of the formula II
Figure imgf000057_0001
wherein
Z1' is oxygen or sulphur; R' is hydrogen, halogen, amino, -NHCO-R2', C3_ -cycloalkyl, C4-10- (cycloalkylalkyi) , -Z2' -C3_7-cycloalkyl optionally substituted with Cι_6-alkyl, -Z2' -C4-10- (cycloalkylalkyi) , -Z2' -C4-10- (cycloalkenylalkyl) , -Z2' -C4-.10- (methylenecycloalkyl-alkyl) , -NH-R2', -NR2'R3', -NH-OR2' , phenyl, phenoxy, benzoyl, benzyloxycarbonyl, tetrahydronaphtyl, indenyl, X', R2' , -Z2'R2', -SOR2*, -S02R2', -Z '-R ,-Z3,-R3', -Z2'-R2'-Z3 ' -R3 '-Z4 '- R4', -Z '-R 'CO-R3', -Z2'-R2'-C02-R3' , Z2'-R2'-02C-R3' , -Z2' -R2' -CONH-R3 ' , -Z2'-R2'- NHCOR3 ' ,
-Z2'-R2'-X', -Z2'-R2'-Z3'-X' , wherein Z2' , Z3 ' , and Z4' independently are oxygen or sulphur, and R2' , R3 ' and R4' independently are straight or branched Cι-15-alkyl, straight or branched C2-i5-alkenyl, straight or branched C2-i5-alkynyl, each of which is optionally substituted with halogen(s), -OH, -CN, -CF3, -SH, -COOH, -NH-R2', -NR2'R3', Cι_6alkyl ester, one or two phenyl, phenoxy, benzoyl or benzyloxycarbonyl wherein each aromatic group is optionally substituted with one or two halogen, -CN, Cι-4-alkyl or Cι_4-alkoxy, and X' is a 5 or 6 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereof, which heterocyclic group iε optionally substituted at carbon or nitrogen atom(ε) with straight or branched Ci-β- alkyl, phenyl, benzyl or pyridine, or a carbon atom in the heterocyclic group together with an oxygen atom form a carbonyl group, or which heterocyclic group is optionally fused with a phenyl group; and
R5' and R6' may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C1-5- alkyl, straight or branched C2-5-alkenyl, straight or branched C2-5-alkynyl, straight or branched Cι-10-alkoxy, straight or branched Cι-5-alkyl subεtituted with -OH, -OH, halogen, -NH2 or carboxy; R1' is hydrogen, straight or branched Cι-5-alkyl, straight or branched C2-5~alkenyl or straight or branched C2-5-alkynyl; or a pharmaceutically acceptable salt or solvate thereof; and one or more nonsteroidal anti-inflammatory drugs in a weight ratio of Formula II to nonsteroidal anti- inflammatory drug of from about 1 to about 1000.
26. A composition of Claim 25 wherein Z' is sulfur.
27. A composition of Claim 25 wherein Z' is sulfur, R1' is hydrogen or straight or branched Cι-5-alkyl, R5' and R6' independently are selected from the group consisitng of hydrogen, methyl, methoxy, hydroxy, halogen, and amino.
28. A composition according to Claim 25 wherein the compound of Formula II is selected from the group consisting of the following:
3- (3-METHOXY-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-ETHOXY-1,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-1- METHYLPYRIDINE 3- (3-PROPOXY-1,2, 5-THIADIAZOL-4-YD -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-BUTOXY-1,2, 5-THIADIAZOL-4-YL) 1, 2, 5, 6-TETTRAHYDRO-l- METHYLPYRIDINE
3- (3-ISOPROPOXY-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CYCLOPROPYLMETHOXY-l,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-PENTOXY-1, 2 , 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-ISOBUTOXY-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (3-BUTENOXY) -1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (BUT-2-YNOXY) -1, 2 , 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (3-METHYLBUTOXY) -1,2, 5-THIADIAZOL- -YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (PROP-2-YNOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2, 5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BENZYLOXY-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE 3-(3-CHLORO-l,2,5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDROPYRIDINE
3- (3-BUTOXY-1,2,5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDROPYRIDINE
3- (3-ETHOXY-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO-1- ETHYLPYRIDINE
3- (3-CHLORO-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO-1- ETHYLPYRIDINE
3- (3-METHOXYETHOXY-l,2, 5-THIADIAZOL- -YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3-HEPTYLOXY-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (3-PENTYNYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-PENTENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-PROPENYLOXY) -1, 2, 5-THIADIAZOL-4-Y ) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-OCTYLOXY-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (3-HEXYNYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2, 5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-BUTENYL-2-OXY) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYL-PYRIDINE 3- (3- (4-HEXENYL0XY(-l,2,5-THIADIAZ0L-4-YL)-l,2, 5,6- TETRAHYDRO-1-METHYLPYRIDINE
TRANS-3- (3- (3-HEXENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3- (3- (2-PENTENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3-(3-(2-HEXENYLOXY)-l,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (5-HEXENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3- (3- (3-HEXENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,4,5- TETRAHYDRO-1-METHYLPYRIDINE
TRANS-3- (3- (2-HEXENYLOXY) -1,2, 5-THIADIAZOL-4-YD-1,2, 5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-METHYLPIPERIDINO-l,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-MORPHOLINO-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-DIMETHYLAMINO-1,2, 5-THIADIAZOL- -YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3-HEXYLAMINO-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- DEUTEROMETHYLPYRIDINE 1,2,5,6-TETRAHYDRO-3- (3-HEXYLOXY-1,2,5-THIADIAZOL-4- YL) PYRIDINE
3- (3- (2- (2-METHOXYETHOXY) -ETHOXY) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-ETHOXY-1-PROPOXY) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6, - TETRAHYDRO-1-METHYLPYRIDINE
3- (2-ETHOXYETHOXY) -1,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (2-BUTOXYETHOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2- (2-BUTOXYETHOXY) -ETHOXY) -1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-l-METHYLPYRIDINE
3-(3-(2- (2-ETHOXYETHOXY) -ETHOXY) -1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-METHYLTHIO-1,2, 5-THIADIAZOL-4-YL)-1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PENTYL-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYLTHIO-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3-HEXYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1, 2 , 5, 6-TETRAHYDRO-l- METHYLPYRIDINE 3- (3-PENTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-ETHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-OCTYLTHIO-l,2, 5-THIADIAZOL- -YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYL-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3-(3-HEPTYL-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (5-HEXENYL) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-OCTYL-1,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYPYRIDINE
3- (3- (2-METHYL) -BUTYL-1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-METHYLCYCLOPROPYL-1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-CYCLOPENTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-(l-ETHYLTHIO-2-METHOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-CHLORO-1-PROPYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3- (2-METHOXYETHOXY) -ETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-l-METHYLPYRIDINE
3- (3- (3-CYANO-1-PROPYLTHIO) -1,2,5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-BENZYLTHIO-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3- (2-ETHOXY-1-ETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-PENTYNYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2- (2-ETHOXYMETHOXY) -ETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (5-CYANO-l-PENTYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-PHENYL-1-PROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-PHENOXYETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-CYANOBUTYLTHIO)-l,2, 5-THIADIAZOL- -YL) -1,2,5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-ETHYLBUTYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-CYCLOHEXYLMETHYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2, 5,6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3- (8-HYDROXYOCTYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (7-OCTENYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-CYCLOPROPYLMETHYLTHIO-1,2, 5-THIADIAZOL-4-YD -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3 (3-CYCLOPROPYLMETHYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1,2, 5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-BUTENYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1, 2 , 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-PENTENYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (4-ISOHEXYLOXY-l,2, 5-THIADIAZOL-3-YD -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
l-METHYL-l,2,5,6-TETRAHYDRO-3- ( (4-CYCLOPENTYLPROPYL)OXY) - 1,2,5-THIADIAZOL-3-YL) PYRIDINE
1-METHYL-1,2, 5, 6-TETRAHYDRO-3- (4-ISOHEPTYLOXY-l, 2, 5- THIADIAZOL-3-YL) PYRIDINE
l-METHYL-l,2,5,6-TETRAHYDRO-3- (4 ( (2-CYCLOHEXYLETHYL)OXY) - 1,2,5-THIADIAZOL-3-YL) PYRIDINE
1,2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (1-METHYLHEXLOXY) -1,2,5- THIADIAZOL-3-YDPYRIDINE
3-(4-(l-ETHYLPENTYLOXY) -1,2, 5-THIADIAZOL-3-YL) -1,2,5, 6- TETRAHYDRO-1-METHYLPYRIDINE 3- (4- (1-ETHYLBUTOXY) -1,2, 5-THIADIAZOL-3-YL) -1, 2 ,5,6- TETRAHYDRO-1-METHYLPYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (1-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-)YDPYRIDINE
1-METHYL-3- (4- (5-HEXENYLOXY) -1,2,5-THIADIAZOL-3-YL) -1,2,5,6- TETRAHYDROPYRIDINE
1, 2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLBUTOXY) -1, 2 , 5- THIADIAZOL-3-YD PYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-YL)PYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (2,2,2-TRIFLUOROETHOXY) - 1,2, 5-THIADIAZOL-3-YL) PYRIDINE
1-METHYL-1,2,5,6-TETRAHYDRO-3- (4- (3-METHYLPENTYLOXY) -1, 2, 5- THIADIAZOL-3-YD PYRIDINE
3- (3- (3-METHYL-2-BUTENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDO-1-METHYLPYRIDINE
3-(3-ISOBUTOXY-l,2,5-THIADIAZOL-4-YL) -1,2 , 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
1,2,5,6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLBUTOXY) -1, 2 , 5- THIADIAZOL-3-YL) PYRIDINE
3- (3- (3-HYDROXYPROPOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6- TETRAHYDRO-1-METHYLPYRIDINE
(+-) l,6-DIMETHYL-3- (3-HEXYLOXY-l,2, 5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDROPYRIDINE 3- (3- (3-PHENYL-ETHYLTHIO)-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
BIS-1, 4- (3- (1-METHYL-1,2,5, 6-TETRAHYDROPYRIDIN-3-YL) -1,2,5- THIADIAZOL-4-YDBUTANEDITHIOL
3- (3- (4,4,4-TRIFLUOROBUTOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5- THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3,3, 3-TRIFLUOROPROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1, 1- DIMETHYLPYRIDINIUM IODIDE
(+-) 1, 6-DIMETHYL-3- (3-BUTYLTHIO-l,2 , 5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDROPYRIDINE
(+-) 1, 6-DIMETHYL-3- (3-BUTOXY-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDROPYRIDINE
3- (3- (3-METHYL-2-BUTENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDO-1-METHYL PYRIDINE
3-(3-ISOBUTOXY-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE
1,2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLBUTOXY) -1,2 , 5- THIADIAZOL-3-YD PYRIDINE 3- (3- (3-HYDR0XYPR0P0XY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
(+-) 1,6-DIMETHYL-3- (3-HEXYLOXY-1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDROPYRIDINE
3-(3-(3-PHENYL-ETHYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
BIS-1, 4- (3- (1-METHYL-1,2, 5, 6-TETRAHYDROPYRIDIN-3-YL) -1,2,5- THIADIAZOL-4-YL)BUTANEDITHIOL
3- (3- (4, 4, 4-TRIFLUOROBUTOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3,3,3-TRIFLUOROPROPYLTHIO)-l,2, 5-THIADIAZOL-4-YL) - 1,2, 5, 6-TETRAHYDRO-1-METHY PYRIDINE
3- (3-PROPYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE
3-(3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-
TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1, 2 , 5, 6-TETRAHYDRO-1, 1- DIMETHYLPYRIDINIUM IODIDE
(+-) 1, 6-DIMETHYL-3- (3-BUTYLTHIO-1,2,5-THIADIAZOL-4-Y ) - 1,2,5, 6-TETRAHYDROPYRIDINE; and
(+-} 1, 6-DIMETHYL-3- (3-BUTOXY-l,2, 5-THIADIAZOL-4-YL) - 1,2, 5, 6-TETRAHYDROPYRIDINE; or a pharmaceutically acceptable salt or solvate thereof. 29. A composition of Claim 25 wherein the the non-steroidal antiinflammatory drug is selected from the group conεiεting of salicylates, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
30. A composition of Claim 29 wherein the non¬ steroidal antiinflammatory drugs is selected from the group consisting of aspirin, ibuprofen, and naproxen.
31. A composition of Claim 25 wherein the weight ratio of a compound of Formula II to NSAIDS is from about 1 to about 100.
32. A composition of Claim 30 wherein the non¬ steroidal antiinflammatory drug is ibuprofen.
33. A composition of Claim 2 wherein the weight ratio of compound of Formula I to NSAIDS is from about 1 to about 100.
34. A method for treating pain comprising administering an analgesic dose of a composition comprising a compound of the formula II
Figure imgf000069_0001
wherein Z1' is oxygen or sulphur;
R' is hydrogen, halogen, amino, -NHCO-R2', C3-7-cycloalkyl, C4-10- (cycloalkylalkyi) , -Z2' -C3-7-cycloalkyl optionally substituted with Cι_6-alkyl, -Z2'-C4-.10- (cycloalkylalkyi) , -Z2' -C4-.10- (cycloalkenylalkyl) , -Z2'-C4_ιo- (methylenecycloalkyl-alkyl) ,
-NH-R2', -NR2'R3', -NH-OR2', phenyl, phenoxy, benzoyl, benzyloxycarbonyl, tetrahydronaphtyl, indenyl, X', R2' , -Z2'R2', -SOR2', -S02R2', -Z2'-R2'-Z3'-R3', -Z2'-R '-Z3' -R3 ' -Z4' - R4', -Z2'-R2'CO-R3' ,
-Z2'-R2'-Cθ2-R3' , Z2'-R2'-θ2C-R3' , -Z2' -R2'-CONH-R3' , -Z2' -R2' - NHCOR3 ' ,
-Z2'-R2'-X' , -Z2'-R2'-Z3'-X' , wherein Z2' , Z3 ' , and Z4' independently are oxygen or sulphur, and R2' , R3 ' and R4' independently are straight or branched Cι-15-alkyl, straight or branched C2-i5-alkenyl, straight or branched C2-i5 _alkynyl, each of which is optionally substituted with halogen(s) , -OH, -CN, -CF3, -SH, -COOH, -NH-R2', -NR2'R3', Ci-ealkyl ester, one or two phenyl, phenoxy, benzoyl or benzyloxycarbonyl wherein each aromatic group is optionally substituted with one or two halogen, -CN, Cι-4-alkyl or
Cι-4-alkoxy, and X' is a 5 or 6 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereof, which heterocyclic group iε optionally εubstituted at carbon or nitrogen atom(s) with straight or branched Cχ_6- alkyl, phenyl, benzyl or pyridine, or a carbon atom in the heterocyclic group together with an oxygen atom form a carbonyl group, or which heterocyclic group iε optionally fused with a phenyl group; and R5' and R6' may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C1-5- alkyl, straight or branched C2-5-alkenyl, straight or branched C2-5-alkynyl, straight or branched Cι-10-alkoxy, straight or branched Cι_5-alkyl substituted with -OH, -OH, halogen, -NH2 or carboxy; R1' is hydrogen, straight or branched Cι_5-alkyl, straight or branched C2-5~alkenyl or straight or branched C2-5~alkynyl; or a pharmaceutically acceptable salt or solvate thereof; and one or more NSAIDS in a weight ratio of Formula II to NSAIDS of from about 1 to about 1000.
35. A method of Claim 34 wherein the non¬ steroidal antiinflammatory drug is selected from the group consisting of salicylates, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
36. A method of Claim 34 wherein the non¬ steroidal antiinflammatory drug iε selected from the group consiεting of ibuprofen, and naproxen.
37 . A method of Claim 35 wherein the composition iε administered using a transdermal formulation.
38. A composition for treating pain comprising an analgesic dose of a Compound selected from the group consisting of Formula I
Figure imgf000071_0001
wherein X is oxygen or sulphur;
R is hydrogen, amino, halogen, -CHO, -NO2, -OR4, -SR4, -SOR4, -SO2R4, C3-.7-cycloalkyl, C4-8- (cycloalkylalkyi) , -Z-C3-7- cycloalkyl, and -Z-C4-8- (cycloalkylalkyi) wherein R4 is straight or branched Cι-15-alkyl, straight or branched C2-15- alkenyl, straight or branched C2-i5-alkynyl, each of which is optionally substituted with one or more halogens, -CF3, -CN, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, Cι-4-alkyl, Cι-4-alkoxy, -OCF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, Cι-4-alkyl, Cι_4-alkoxy, -OCF3, -CONH or -CSNH2; or R is -OR5Y, -SR5Y, -OR5ZY, -SR5ZY, -0-R4-Z- R5 or -S-R -Z-R5 wherein Z iε oxygen or sulphur, R5 is straight or branched Cι-15-alkynyl, and Y is a 5 or 6 membered heterocyclic group containing one to four N, 0 or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched Cι-6-alkyl, phenyl or benzyl, or which heterocyclic group is optionally fused with a phenyl group; and G is selected from one of the following azabicyclic rings
Figure imgf000072_0001
wherein the thiadiazole or oxadiazole ring can be attached at any carbon atom of the azabicyclic ring; R1 and R2 may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C1-.5- alkyl, straight or branched C2-5 alkenyl, straight or branched C2-5~alkynyl, straight or branched Cχ_ιo-alkoxy, straight or branched Cι-5-alkyl subεtituted with -OH, OR4, halogen, -NH2 or carboxy; R3 is H, straight or branched Cι_ 5-alkyl, straight or branched C2-5~alkenyl or straight or branched C2-5~alkynyl; n is 0, 1 or 2 ; m is 0, 1 or 2; p is
0, 1 or 2; q is 1 or 2; and iε a εingle or double bond; and Formula II
Figure imgf000073_0001
wherein
Z1' is oxygen or sulphur;
R' is hydrogen, halogen, amino, -NHCO-R2', C3-7-cycloalkyl, C4-10- (cycloalkylalkyi) , -Z2' -C3_7-cycloalkyl optionally substituted with Cι-6-alkyl, -Z2' -C4-10- (cycloalkylalkyi) , -Z2' -C4-10- (cycloalkenylalkyl) , -Z2'-C4_ιo- (methylenecycloalkyl-alkyl) ,
-NH-R2', -NR2'R3', -NH-OR2', phenyl, phenoxy, benzoyl, benzyloxycarbonyl, tetrahydronaphtyl, indenyl, X', R2' , -Z2'R2', -SOR2', -S02R2', -Z2'-R2'-Z3'-R3' , -Z2' -R2 ' -Z3 ' -R3 '-Z4'- R4', -Z2'-R2'CO-R3',
-Z2'-R2'-C02-R3' , Z2'-R2'-0 C-R3' , -Z2' -R2' -CONH-R3 ' , -Z2' -R2' - NHCOR3 ' ,
-Z2'-R '-X', -Z2'-R2'-Z3'-X' , wherein Z2' , Z3', and Z4' independently are oxygen or sulphur, and R2' , R3 ' and R ' independently are straight or branched Cι-15-alkyl, straight or branched C2-ιs-alkenyl, straight or branched C2-ιs-alkynyl, each of which is optionally substituted with halogen(s) , -OH, -CN, -CF3, -SH, -COOH, -NH-R2', -NR2'R3', Cι-6alkyl ester, one or two phenyl, phenoxy, benzoyl or benzyloxycarbonyl wherein each aromatic group is optionally substituted with one or two halogen, -CN, Cι_4-alkyl or C1-4-alkoxy, and X' is a 5 or 6 membered heterocyclic group containing one to four N, 0 or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched Cι_6- alkyl, phenyl, benzyl or pyridine, or a carbon atom in the heterocyclic group together with an oxygen atom form a carbonyl group, or which heterocyclic group iε optionally fused with a phenyl group; and R5' and R6' may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C1-5- alkyl, straight or branched C2-5-alkenyl, straight or branched C2-5-alkynyl, straight or branched Cι_ιo-alkoxy, straight or branched Cι-5-alkyl substituted with -OH, -OH, halogen, -NH2 or carboxy; R1' is hydrogen, straight or branched Cι_5-alkyl, straight or branched C2-5~alkenyl or straight or branched C2-5-alkynyl; or a pharmaceutically acceptable salt or solvate thereof; and acetaminophen in a weight ratio of Compound to acetaminophen of from about 1 to about 1000.
39. A composition of Claim 38 wherein the compound is a compound of Formula I; or a pharmaceutically acceptable salt or solvate thereof.
40. A composition of Claim 39 wherein X is S, G
Figure imgf000074_0001
wherein n is 1, p is 1 or 2 and m is 1 or 2, R1 and R2 independently are hydrogen, methyl, hydroxy, halogen or amino; or a pharmaceutically acceptable salt or solvate thereof. 41. A composition of Claim 39 wherein X is S,
Figure imgf000075_0001
wherein n is 1, p is 1 or 2 and m is 1 or 2
42. A composition according to Claim 39 wherein the compound of Formula I is selected from the group consisting of the following:
3-CHLORO-3- (3-CHLORO-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO[2.2.2]OCTANE;
3- (3-CHLORO-l,2, 5-THIADIAZOL-4-YL) -3-HYDROXY-1- AZABICYCLO[2.2.2]OCTANE;
3-METHOXY-3- (3-METHOXY-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[2.2.2]OCTANE;
3- (3-METHOXY-l,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO[2.2.2]OCT-2- ENE;
3- (3-HEXYLOXY-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO[2.2.2]OCT- 2-ENE;
3-HEXYLOXY-3- (3-HEXYLOXY-1,2 , 5-THIADIAZOL-4-YL) -1-AZABICYCLO- [2.2.2]OCTANE;
3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) -3-HYDROXY-l- AZABICYCLO[2.2.2]OCTANE;
3- (3-CHLORO-l,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO [ 2.2.2]OCTANE;
3- (3-ETHOXY-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO [2.2.2]OCTANE; 3- (3-PROPOXY-l,2,5-THIADIAZOL-4-YL)-l- AZABICYCLO [2.2.2]OCTANE;
3- (3-BUTOXY-l,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO [2.2.2]OCTANE;
3- (3-PENTYLTHIO-1,2, 5-THIADIAZOL-4-Y ) -1-AZABICYCL0- [2.2.2]OCTANE;
3- (3-ETHOXY-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO [2.2.2]OCTANE;
3- (3-HEXYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1- AZABICYCL0 [2.2.2]OCTANE;
3- (3- (3-PHENYLPROPYLTHIO)-l,2,5-THIADIAZOL-4-YL)-l- AZABICYCLO[2.2.2]OCTANE;
3- (3-HEXYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
3- (3- (4-CYANOBENZYLTHIO) -1,2 , 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
EXO-6- (3-CHLORO-1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-HEXYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3- (5-HEXENYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-BUTYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE; ENDO-6- (3-PENTYLTHIO-l, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-ETHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE; and
ENDO-6- (3- (3-PHENYLPROPYLTHIO)-l,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE; or a pharmaceutically acceptable salt or solvate thereof.
43. A composition of Claim 42 wherein the Compound of Formula I is 3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE; or a pharmaceutically acceptable salt or εolvate thereof.
44. A compoεition of Claim 43 wherein the weight ratio is from about 1 to about 30.
45. A composition of Claim 38 wherein the compound is of Formula II.
46. A composition of Claim 45 wherein Z is sulfur.
47. A composition of Claim 45 wherein Z is sulfur, R1 is hydrogen or straight or branched Cι-5-alkyl, R5 and R6 independently are selected from the group consisitng of hydrogen, methyl, methoxy, hydroxy, halogen, and amino.
48. A composition according to Claim 45 wherein the compound of Formula II is selected from the group consisting of the following: 3- (3-METHOXY-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-ETHOXY-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPOXY-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-BUTOXY-1,2, 5-THIADIAZOL-4-YL) 1, 2, 5, 6-TETTRAHYDRO-l- METHYLPYRIDINE
3- (3-ISOPROPOXY-1,2,5-THIADIAZOL-4-Y ) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CYCLOPROPYLMETHOXY-l,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-PENTOXY-l,2,5-THIADIAZOL-4-YD -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-ISOBUTOXY-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (3-BUTENOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3-(3-(BUT-2-YNOXY)-l,2,5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (3-METHYLBUTOXY) -1, 2,5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE 3-(3-(PROP-2-YNOXY)-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BENZYLOXY-1,2,5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CHLORO-1,2,5-THIADIAZOL- -YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CHLORO-1,2,5-THIADIAZOL- -YL) -1, 2, 5, 6-TETRAHYDROPYRIDINE
3- (3-BUTOXY-1,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDROPYRIDINE
3- (3-ETHOXY-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- ETHYLPYRIDINE
3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YD-1,2, 5, 6-TETRAHYDRO-1- ETHYLPYRIDINE
3- (3-METHOXYETHOXY-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3-HEPTYLOXY-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE
3-(3-(3-PENTYNYLOXY)-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-(4-PENTENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-(2-PROPENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-OCTYLOXY-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE 3- (3- (3-HEXYNYLOXY)-l,2,5-THIADIAZOL-4-YL)-l,2, 5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-BUTENYL-2-OXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYL-PYRIDINE
3- (3- (4-HEXENYLOXY(-1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
TRANS-3- (3- (3-HEXENYLOXY)-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3- (3- (2-PENTENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5 , 6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3- (3- (2-HEXENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (5-HEXENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3-(3- (3-HEXENYLOXY)-l,2, 5-THIADIAZOL-4-YL) -1,2, 4, 5- TETRAHYDRO-1-METHYLPYRIDINE
TRANS-3- (3- (2-HEXENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-METHYLPIPERIDINO-1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5 , 6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-MORPHOLINO-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3-DIMETHYLAMINO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE 3-(3-HEXYLAMINO-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- DEUTEROMETHYLPYRIDINE
1,2,5, 6-TETRAHYDRO-3- (3-HEXYLOXY-l, 2, 5-THIADIAZOL-4- YL) PYRIDINE
3- (3- (2- (2-METHOXYETHOXY) -ETHOXY) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-ETHOXY-1-PROPOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6,- TETRAHYDRO-1-METHYLPYRIDINE
3- (2-ETHOXYETHOXY) -1, 2 , 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (2-BUTOXYETHOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2, 5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2- {2-BUTOXYETHOXY) -ETHOXY) -1, 2 , 5-THIADIAZOL-4-YL) - 1, 2, 5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2- (2-ETHOXYETHOXY) -ETHOXY) -1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BUTYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-METHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PENTYL-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE 3- (3-PROPYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-HEXYLTHIO-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3-PENTYLTHIO-l,2,5-THIADIAZOL-4-YD-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3-ETHYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-OCTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYL-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-HEPTYL-l,2, 5-THIADIAZOL- -YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (5-HEXENYL) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-OCTYL-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYPYRIDINE
3- (3- (2-METHYL) -BUTYL-1,2, 5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-METHYLCYCLOPROPYL-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-CYCLOPENTYLTHIO-1,2,5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3-Q-ETHYLTHIO-2-METHOXY) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-CHLORO-l-PROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-METHOXYETHOXY) -ETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-CYANO-1-PROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BENZYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (2-ETHOXY-1-ETHYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-PENTYNYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2- (2-ETHOXYMETHOXY) -ETHYLTHIO) -1,2, 5-THIADIAZOL-4-YD - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (5-CYANO-l-PENTYLTHIO) -1,2, 5-THIADIAZOL-4-YD -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-PHENYL-1-PROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-PHENOXYETHYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-CYANOBUTYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE 3-(3-(2-ETHYLBUTYLTHIO)-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-CYCLOHEXYLMETHYLTHIO-l, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (8-HYDROXYOCTYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (7-OCTENYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-CYCLOPROPYLMETHYLTHIO-1,2,5-THIADIAZOL-4-YL) -1, 2 , 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3 (3-CYCLOPROPYLMETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-BUTENYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-(4-PENTENYLTHIO)-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (4-ISOHEXYLOXY-1,2,5-THIADIAZOL-3-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
1-METHYL-1,2,5,6-TETRAHYDRO-3- ( (4-CYCLOPENTYLPROPYL)OXY) - 1,2,5-THIADIAZOL-3-YL) PYRIDINE
l-METHYL-1,2, 5, 6-TETRAHYDRO-3- (4-ISOHEPTYLOXY-l,2 , 5- THIADIAZOL-3-Y ) PYRIDINE
1-METHYL-1,2,5,6-TETRAHYDRO-3- (4 ( (2-CYCLOHEXYLETHYL)OXY) - 1,2, 5-THIADIAZOL-3-YD PYRIDINE 1,2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (1-METHYLHEXLOXY) -1,2,5- THIADIAZOL-3-YD PYRIDINE
3- (4- (l-ETHYLPENTYLOXY)-l,2,5-THIADIAZOL-3-YL)-l,2,5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (4- (1-ETHYLBUTOXY) -1, 2, 5-THIADIAZOL-3-YL) -1, 2 , 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (1-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-)YL) PYRIDINE
l-METHYL-3- (4- (5-HEXENYLOXY) -1,2, 5-THIADIAZOL-3-YD -1, 2, 5, 6- TETRAHYDROPYRIDINE
1,2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLBUTOXY) -1,2,5- THIADIAZOL-3-YD PYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-YL) PYRIDINE
1,2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (2 , 2, 2-TRIFLUOROETHOXY) - 1,2,5-THIADIAZOL-3-YL) PYRIDINE
1-METHYL-1,2,5, 6-TETRAHYDRO-3- (4- (3-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-YL)PYRIDINE
3- (3- (3-METHYL-2-BUTENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDO-1-METHYLPYRIDINE
3- (3-ISOBUTOXY-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
1,2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLBUTOXY) -1,2,5- THIADIAZOL-3-Y PYRIDINE 3- (3- (3-HYDROXYPROPOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
(+-) 1, 6-DIMETHYL-3- (3-HEXYLOXY-l,2, 5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDROPYRIDINE
3- (3- (3-PHENYL-ETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
B Ξ-1,4- (3-(l-METHYL-l,2,5,6-TETRAHYDROPYRIDIN-3-YD-l,2,5- THIADIAZOL-4-YL) BUTANEDITHIOL
3- (3- (4, 4, 4-TRIFLUOROBUTOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5- THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3 , 3 , 3-TRIFLUOROPROPYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1, 1- DIMETHYLPYRIDINIUM IODIDE
(+-) 1, 6-DIMETHYL-3- (3-BUTYLTHIO-1, 2, 5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDROPYRIDINE
(+-) 1, 6-DIMETHYL-3- (3-BUTOXY-l,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE
3- (3- (3-METHYL-2-BUTENYLOXY) -1,2,5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDO-1-METHYL PYRIDINE 3- (3-ISOBUTOXY-l,2, 5-THIADIAZOL-4-YL) -1, 2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLBUTOXY) -1,2,5- THIADIAZOL-3-YL) PYRIDINE
3- (3- (3-HYDROXYPROPOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
(+-) 1, 6-DIMETHYL-3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDROPYRIDINE
3- (3- (3-PHENYL-ETHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
BIS-1, 4- (3- (1-METHYL-1,2,5,6-TETRAHYDROPYRIDIN-3-YL) -1,2, 5- THIADIAZOL-4-YL)BUTANEDITHIOL
3- (3- (4, 4, 4-TRIFLUOROBUTOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3,3,3-TRIFLUOROPROPYLTHIO)-l,2,5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE
3-(3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1, 1- DIMETHYLPYRIDINIUM IODIDE (+-) 1, 6-DIMETHYL-3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDROPYRIDINE; and
(+-) 1, 6-DIMETHYL-3- (3-BUTOXY-l,2,5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDROPYRIDINE; or a pharmaceutically acceptable salt or solvate thereof.
49. A composition of Claim 45 wherein the weight ratio of a compound of Formula II to acetaminophen of from about 1 to about 100.
50. A method for treating pain comprising administering an analgesic dose of a composition comprising a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and acetaminophen in a weight ratio of Compound to acetaminophen of from about 1 to about 1000.
51. A method of Claim 50 wherein the compound is of Formula I.
52. A method of Claim 51 wherein the weight ratio of a compound of Formula I to acetaminophen of from about 1 to about 100.
53. A method of Claim 51 wherein the composition is administered using a transdermal formulation.
54. A method of Claim 51 wherein the Formula I compound is 3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCL0[2.2.2]OCTANE; or a pharmaceutically acceptable salt or solvate thereof.
55. A method of Claim 50 wherein the compound is of Formula II. 56. A method of Claim 55 wherein the compound is εelected from the group consisting of
3- (3-METHOXY-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-ETHOXY-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPOXY-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-BUTOXY-1,2, 5-THIADIAZOL-4-YL) 1, 2, 5, 6-TETTRAHYDRO-l- METHYLPYRIDINE
3- {3-ISOPROPOXY-1,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CYCLOPROPYLMETHOXY-l,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-PENTOXY-l,2,5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-ISOBUTOXY-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3-(3-(3-BUTENOXY)-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3-(3-(BUT-2-YNOXY)-l,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (3-METHYLBUTOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3-HEXYLOXY-1,2, 5-THIADIAZOL-4-Y ) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (PROP-2-YNOXY) -1,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BENZYLOXY-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3-CHLORO-1,2, 5-THIADIAZOL- -YL) -1, 2, 5, 6-TETRAHYDROPYRIDINE
3- (3-BUTOXY-1,2, 5-THIADIAZOL-4-YD -1,2,5, 6-TETRAHYDROPYRIDINE
3- (3-ETHOXY-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- ETHYLPYRIDINE
3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- ETHYLPYRIDINE
3- (3-METHOXYETHOXY-1,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3-HEPTYLOXY-l,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (3-PENTYNYLOXY) -1,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-(4-PENTENYLOXY)-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-PROPENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3-OCTYLOXY-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (3-HEXYNYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-BUTENYL-2-OXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYL-PYRIDINE
3- (3- (4-HEXENYLOXY(-1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
TRANS-3- (3- (3-HEXENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3- (3- (2-PENTENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3- (3-(2-HEXENYLOXY)-l,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (5-HEXENYLOXY)-l,2,5-THIADIAZOL-4-YL)-l,2, 5,6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3- (3- (3-HEXENYLOXY) -1,2, 5-THIADIAZOL- -YL) -1,2,4,5- TETRAHYDRO-1-METHYLPYRIDINE
TRANS-3- (3- (2-HEXENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-(4-METHYLPIPERIDINO-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-MORPHOLINO-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE 3- (3-DIMETHYLAMINO-l, 2, 5-THIADIAZOL- -YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3-HEXYLAMINO-l,2, 5-THIADIAZOL-4-YD -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-HEXYLOXY-l,2,5-THIADIAZOL-4-YL)-l,2, 5, 6-TETRAHYDRO-1- DEUTEROMETHYLPYRIDINE
1,2,5,6-TETRAHYDRO-3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4- YL) PYRIDINE
3- (3- (2- (2-METHOXYETHOXY) -ETHOXY) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-ETHOXY-l-PROPOXY)-l,2,5-THIADIAZOL-4-YL)-l,2,5,6, - TETRAHYDRO-1-METHYLPYRIDINE
3- (2-ETHOXYETHOXY) -1,2 , 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (2-BUTOXYETHOXY) -1, 2, 5-THIADIAZOL-4-Y ) -1, 2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2- (2-BUTOXYETHOXY) -ETHOXY) -1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-l-METHYLPYRIDINE
3- (3- (2- (2-ETHOXYETHOXY) -ETHOXY) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BUTYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-METHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE 3- (3-PENTYL-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-HEXYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PENTYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-ETHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-OCTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYL-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-HEPTYL-l,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (5-HEXENYL) -1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-OCTYL-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYPYRIDINE
3- (3- (2-METHYL) -BUTYL-1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-METHYLCYCLOPROPYL-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3-CYCLOPENTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (l-ETHYLTHIO-2-METHOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- ( - (3-CHLORO-1-PROPYLTHIO) -1,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-METHOXYETHOXY) -ETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-CYANO-l-PROPYLTHIO)-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BENZYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (2-ETHOXY-1-ETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-PENTYNYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2- (2-ETHOXYMETHOXY) -ETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (5-CYANO-l-PENTYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-PHENYL-l-PROPYLTHIO) -1,2,5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-PHENOXYETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3-(4-CYANOBUTYLTHIO)-l,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-ETHYLBUTYLTHIO) -1, 2, 5-THIADIAZOL-4-YD -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-CYCLOHEXYLMETHYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-(8-HYDROXYOCTYLTHIO)-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (7-OCTENYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1, 2 , 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-CYCLOPROPYLMETHYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3 (3-CYCLOPROPYLMETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-BUTENYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2 ,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-PENTENYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (4-ISOHEXYLOXY-l, 2, 5-THIADIAZOL-3-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
1-METHYL-1,2, 5, 6-TETRAHYDRO-3- ( (4-CYCLOPENTYLPROPYL)OXY) - 1,2, 5-THIADIAZOL-3-YL) PYRIDINE
1-METHYL-1,2,5, 6-TETRAHYDRO-3- (4-ISOHEPTYLOXY-l, 2,5- THIADIAZOL-3-YL) PYRIDINE 1-METHYL-1, 2,5, 6-TETRAHYDRO-3- (4 ( (2-CYCLOHEXYLETHYL)OXY) - 1,2,5-THIADIAZOL-3-YL) PYRIDINE
1,2,5,6-TETRAHYDRO-1-METHYL-3- (4- (1-METHYLHEXLOXY) -1,2,5- THIADIAZOL-3-YL) PYRIDINE
3- (4- (l-ETHYLPENTYLOXY)-l,2, 5-THIADIAZOL-3-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (4- (l-ETHYLBUTOXY)-l,2,5-THIADIAZOL-3-YL)-l,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (1-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-)YDPYRIDINE
l-METHYL-3- (4- (5-HEXENYLOXY) -1,2, 5-THIADIAZOL-3-YL) -1,2,5,6- TETRAHYDROPYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLBUTOXY) -1,2,5- THIADIAZOL-3-YL) PYRIDINE
1,2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-YL)PYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (2 , 2,2-TRIFLUOROETHOXY) - 1,2,5-THIADIAZOL-3-YL)PYRIDINE
l-METHYL-1,2,5, 6-TETRAHYDRO-3- (4- (3-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-YL)PYRIDINE
3- (3- (3-METHYL-2-BUTENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6- TETRAHYDO-1-METHYLPYRIDINE
3- (3-ISOBUTOXY-l,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE 1, 2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLBUTOXY) -1,2,5- THIADIAZOL-3-YL) PYRIDINE
3- (3- (3-HYDROXYPROPOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
(+-)l,6-DIMETHYL-3-(3-HEXYLOXY-l,2,5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDROPYRIDINE
3- (3- (3-PHENYL-ETHYLTHIO)-l,2,5-THIADIAZOL-4-YL)-l,2, 5,6- TETRAHYDRO-1-METHYLPYRIDINE
BIS-l,4-(3-(l-METHYL-1,2,5,6-TETRAHYDROPYRIDIN-3-YL) -1, 2, 5- THIADIAZOL-4-YL)BUTANEDITHIOL
3- (3- (4, 4, 4-TRIFLUOROBUTOXY) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5- THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3,3, 3-TRIFLUOROPROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1, 1- DIMETHYLPYRIDINIUM IODIDE
(+-) 1, 6-DIMETHYL-3- (3-BUTYLTHIO-1,2 , 5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDROPYRIDINE
(+-) 1, 6-DIMETHYL-3- (3-BUTOXY-1,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDROPYRIDINE 3- (3- (3-METHYL-2-BUTENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDO-1-METHYL PYRIDINE
3- (3-IΞOBUTOXY-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLBUTOXY) -1,2,5- THIADIAZOL-3-YL)PYRIDINE
3- (3- (3-HYDROXYPROPOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
(+-) 1, 6-DIMETHYL-3- (3-HEXYLOXY-l,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDROPYRIDINE
3- (3- (3-PHENYL-ETHYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
BIS-1,4- (3- (l-METHYL-1,2,5, 6-TETRAHYDROPYRIDIN-3-YL) -1, 2, 5- THIADIAZOL-4-YL)BUTANEDITHIOL
3- (3- (4, 4, 4-TRIFLUOROBUTOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3,3, 3-TRIFLUOROPROPYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-PROPYLTHIO-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1,2,5-THIADIAZOL-4-YL) -1,2 , 5, 6- TETRAHYDROPYRIDINE 3- (3-BUTYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1, 1- DIMETHYLPYRIDINIUM IODIDE
(+-) 1, 6-DIMETHYL-3- (3-BUTYLTHIO-1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDROPYRIDINE; and
(+-) 1, 6-DIMETHYL-3- (3-BUTOXY-1, 2, 5-THIADIAZOL-4-YL) -
1,2, 5, 6-TETRAHYDROPYRIDINE; or a pharmaceutically acceptable salt thereof. 57. A composition for treating pain comprising a
Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and a central alpha-adrenergic active compound in a weight ratio of Compound to central alpha-adrenergic active compound of from about 1 to about 1000.
58. A composition of Claim 57 wherein the Compound is of Formula I.
59. A composition according to Claim 58 wherein the Compound of Formula I is selected from the group consisting of the following:
3-CHLORO-3- (3-CHLORO-l,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[2.2.2]OCTANE;
3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -3-HYDROXY-1- AZABICYCLO[2.2.2]OCTANE;
3-METHOXY-3- (3-METHOXY-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[2.2.2]OCTANE;
3- (3-METHOXY-l,2,5-THIADIAZOL-4-YD -1-AZABICYCLO[2.2.2]OCT-2- ENE;
3- (3-HEXYLOXY-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO[2.2.2]OCT- 2-ENE; 3 -HEXYLOXY-3 - ( 3 -HEXYLOXY-l , 2 , 5 -THIADIAZOL-4 -YL ) -l -AZABICYCLO- [ 2 . 2 . 2 ] OCTANE;
3- (3-HEXYLOXY-1,2,5-THIADIAZOL-4-YL) -3-HYDROXY-l- AZABICYCLO[2.2.2]OCTANE;
3- (3-CHLORO-1,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO[2.2.2]OCTANE;
3- (3-ETHOXY-1,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO [2.2.2]OCTANE;
3- (3-PROPOXY-l, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
3- (3-BUTOXY-1,2, 5-THIADIAZOL-4-YL)-1-AZABICYCL0[2.2.2JOCTANE;
3- (3-PENTYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLθ- [2.2.2]OCTANE;
3-(3-ETHOXY-l,2,5-THIADIAZOL-4-YL)-l-AZABICYCL0[2.2.2]OCTANE;
3- (3-HEXYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
3- (3- (3-PHENYLPROPYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2JOCTANE;
3- (3-HEXYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
3- (3- (4-CYANOBENZYLTHIO)-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
EXO-6- (3-CHLORO-l, 2, 5-THIADIAZOL- -YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-CHLORO-l,2, 5-THIADIAZOL-4-YL) -1- AZABIC CLO[3.2.1]OCTANE; ENDO-6- (3-HEXYLTHIO-l,2,5-THIADIAZOL-4-YL)-l- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3- (5-HEXENYLTHIO)-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-BUTYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-PENTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-ETHYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE; and
ENDO-6- (3- (3-PHENYLPROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE; or a pharmaceutically acceptable salt or solvate thereof.
60. A composition of Claim 59 wherein the Compound of Formula I is 3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE; or a pharmaceutically acceptable salt thereof.
61. A composition of Claim 58 wherin the weight ratio of Compound to central alpha-adrenergic active compound of from about 1 to about 30.
62. A composition of Claim 61 wherein the alpha-adrenergic compound is 2- (2, 6-dichlorophenylamino) -2- i idazoline.
63. A composition of Claim 57 wherein the Compound is of Formula II. 64. A composition of Claim 63 wherein the Compound of Formula II is selected from the group consisting of
3-(3-METHOXY-l,2,5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-ETHOXY-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3-PROPOXY-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-BUTOXY-1,2, 5-THIADIAZOL-4-YL) 1, 2, 5, 6-TETTRAHYDRO-l- METHYLPYRIDINE
3- (3-ISOPROPOXY-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CYCLOPROPYLMETHOXY-l,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-PENTOXY-l,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3-(3-ISOBUTOXY-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3- (3-BUTENOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (BUT-2-YNOXY) -1,2 , 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (3-METHYLBUTOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (PROP-2-YNOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BENZYLOXY-1,2,5-THIADIAZOL-4-Y ) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CHLORO-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDROPYRIDINE
3- (3-BUTOXY-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDROPYRIDINE
3- (3-ETHOXY-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- ETHYLPYRIDINE
3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- ETHYLPYRIDINE
3- (3-METHOXYETHOXY-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3-HEPTYLOXY-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3- (3-PENTYNYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-(4-PENTENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-(2-PROPENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3-OCTYLOXY-l, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (3-HEXYNYLOXY)-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-(3-BUTENYL-2-OXY) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYL-PYRIDINE
3- (3-(4-HEXENYLOXY(-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
TRANS-3- (3- (3-HEXENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3- (3- (2-PENTENYLOXY)-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3- (3- (2-HEXENYLOXY) -1,2, 5-THIADIAZOL-4-YD -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (5-HEXENYLOXY) -1, 2, 5-THIADIAZOL-4-YL)-l, 2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3- (3- (3-HEXENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,4,5- TETRAHYDRO-1-METHYLPYRIDINE
TRANS-3- (3- (2-HEXENYLOXY) -1, 2,5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-l-METHYLPYRIDINE
3- (3- (4-METHYLPIPERIDINO-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-MORPHOLINO-l,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE 3- (3-DIMETHYLAMINO-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3-HEXYLAMINO-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- DEUTEROMETHYLPYRIDINE
1,2,5, 6-TETRAHYDRO-3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4- YL) PYRIDINE
3- (3- (2- (2-METHOXYETHOXY) -ETHOXY) -1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-l-METHYLPYRIDINE
3- (3- (3-ETHOXY-1-PROPOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2, 5,6,- TETRAHYDRO-1-METHYLPYRIDINE
3- (2-ETHOXYETHOXY) -1,2 , 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (2-BUTOXYETHOXY) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2- (2-BUTOXYETHOXY) -ETHOXY) -1, 2 , 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2- (2-ETHOXYETHOXY) -ETHOXY) -1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1, 2 , 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-METHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1, 2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE 3-(3-PENTYL-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-HEXYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PENTYLTHIO-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3-ETHYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-OCTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYL-l, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-l- METHYLPYRIDINE
3-(3-HEPTYL-l,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3- (5-HEXENYL) -1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-OCTYL-l,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYPYRIDINE
3- (3- (2-METHYL) -BUTYL-1, 2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-METHYLCYCLOPROPYL-1,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3-CYCLOPENTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-(l-ETHYLTHIO-2-METHOXY) -1,2, -THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-CHLORO-1-PROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-METHOXYETHOXY) -ETHYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-CYANO-1-PROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BENZYLTHIO-l, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-(2-ETHOXY-l-ETHYLTHIO)-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-PENTYNYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2- (2-ETHOXYMETHOXY) -ETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (5-CYANO-l-PENTYLTHIO) -1, 2, 5-THIADIAZOL-4-YD -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-PHENYL-1-PROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-PHENOXYETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1, 2,5,6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3- (4-CYANOBUTYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-ETHYLBUTYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-CYCLOHEXYLMETHYLTHIO-l, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (8-HYDROXYOCTYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (7-OCTENYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-CYCLOPROPYLMETHYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3 (3-CYCLOPROPYLMETHYLTHIO) -1,2, 5-THIADIAZOL- -YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-BUTENYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1, 2 , 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-{4-PENTENYLTHIO)-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (4-ISOHEXYLOXY-l, 2, 5-THIADIAZOL-3-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
1-METHYL-1,2, 5, 6-TETRAHYDRO-3- ( (4-CYCLOPENTYLPROPYL)OXY) - 1,2,5-THIADIAZOL-3-YL)PYRIDINE
1-METHYL-l,2,5,6-TETRAHYDRO-3- (4-ISOHEPTYLOXY-l, 2,5- THIADIAZOL-3-YL) PYRIDINE 1-METHYL-1, 2,5, 6-TETRAHYDRO-3- (4 ( (2-CYCLOHEXYLETHYL)OXY) - 1,2,5-THIADIAZOL-3-YL)PYRIDINE
1,2, 5, 6-TETRAHYDRO-l-METHYL-3- (4- (1-METHYLHEXLOXY) -1,2,5- THIADIAZOL-3-YDPYRIDINE
3- (4- (1-ETHYLPENTYLOXY) -1,2, 5-THIADIAZOL-3-Y ) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (4- (l-ETHYLBUTOXY)-l,2,5-THIADIAZOL-3-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (1-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-)YL) PYRIDINE
l-METHYL-3- (4- (5-HEXENYLOXY) -1,2, 5-THIADIAZOL-3-YL) -1,2,5,6- TETRAHYDROPYRIDINE
1,2, 5, 6-TETRAHYDRO-l-METHYL-3- (4- (2-METHYLBUTOXY)-1, 2 , 5- THIADIAZOL-3-YL) PYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-YD PYRIDINE
1, 2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (2,2, 2-TRIFLUOROETHOXY) - 1,2, 5-THIADIAZOL-3-YL)PYRIDINE
l-METHYL-1,2,5, 6-TETRAHYDRO-3- (4- (3-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-YL)PYRIDINE
3- (3- (3-METHYL-2-BUTENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDO-1-METHYLPYRIDINE
3-(3-ISOBUTOXY-l,2,5-THIADIAZOL-4-YD-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE 1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLBUTOXY) -1,2,5- THIADIAZOL-3-YL)PYRIDINE
3- (3- (3-HYDROXYPROPOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6- TETRAHYDRO-1-METHYLPYRIDINE
(+-) 1, 6-DIMETHYL-3- (3-HEXYLOXY-l,2, 5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDROPYRIDINE
3- (3- (3-PHENYL-ETHYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
BIS-1,4- (3- (l-METHYL-1,2,5, 6-TETRAHYDROPYRIDIN-3-YL) -1,2,5- THIADIAZOL-4-YL)BUT NEDITHIOL
3- (3- (4,4, 4-TRIFLUOROBUTOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5- THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3 ,3 , 3-TRIFLUOROPROPYLTHIO) -1,2,5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1, 1- DIMETHYLPYRIDINIUM IODIDE
(+-)l,6-DIMETHYL-3-(3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YD- 1,2,5, 6-TETRAHYDROPYRIDINE
(+-) 1, 6-DIMETHYL-3- (3-BUTOXY-1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE 3- (3-(3-METHYL-2-BUTENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDO-1-METHYL PYRIDINE
3- (3-ISOBUTOXY-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
1,2,5, 6-TETRAHYDRO-l-METHYL-3- (4- (2-METHYLBUTOXY) -1,2,5- THIADIAZOL-3-YL)PYRIDINE
3- (3- (3-HYDROXYPROPOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
(+-) 1, 6-DIMETHYL-3- (3-HEXYLOXY-1,2, 5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDROPYRIDINE
3- (3- (3-PHENYL-ETHYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
BIS-1,4- (3- (1-METHYL-l, 2, 5, 6-TETRAHYDROPYRIDIN-3-YD -1,2,5- THIADIAZOL-4-YL)BUTANEDITHIOL
3- (3- (4, 4, 4-TRIFLUOROBUTOXY) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3 , 3 , 3-TRIFLUOROPROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-l-METHYLPYRIDINE
3- (3-PROPYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1, 2.5, 6- TETRAHYDROPYRIDINE
3-(3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDROPYRIDINE 3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1, 1- DIMETHYLPYRIDINIUM IODIDE
(+-) 1, 6-DIMETHYL-3- (3-BUTYLTHIO-1,2,5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDROPYRIDINE; and
(+-) l,6-DIMETHYL-3- (3-BUTOXY-l,2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDROPYRIDINE; or a pharmaceutically acceptable salt or solvate thereof.
65. A method for treating pain comprising administering to a patient in need thereof, a composition comprising a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and a central alpha-adrenergic active compound in a weight ratio of Compound to central alpha-adrenergic active compound of from about 1 to about 1000.
66. A method of Claim 65 wherein the Compound is of Formula I.
67. A method of Claim 66 wherein the Compound is 3- (3-BUTYLTHIO-1,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE; or a pharmaceutically acceptable salt or solvate thereof.
68. A method of Claim 65 wherein the Compound is of Formula II.
69. A composition for treating pain comprising an analgesic dose of a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and one or more opioid compounds in a weight ratio of Compound to opioid compound of from about 1 to about 1000. 70. A composition of Claim 69 wherein the Compound is of Formula I.
71. A composition of Claim 70 wherein the compound of Formula I is selected from the group consisting of the following:
3-CHLORO-3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[2.2.2]OCTANE;
3- (3-CHLORO-l,2,5-THIADIAZOL-4-YL)-3-HYDROXY-l- AZABICYCLO[2.2.2]OCTANE;
3-METHOXY-3- (3-METHOXY-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[2.2.2]OCTANE,•
3- (3-METHOXY-l,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO[2.2.2]OCT-2- ENE;
3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO[2.2.2]OCT- 2-ENE;
3-HEXYLOXY-3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO- [2.2.2JOCTANE;
3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) -3-HYDROXY-1- AZABICYCLO[2.2.2]OCTANE;
3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO[2.2.2]OCTANE;
3- (3-ETHOXY-l,2,5-THIADIAZOL-4-YL) -1-AZABICYCLO [2.2.2]OCTANE;
3- (3-PROPOXY-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCL0 [2.2.2]OCTANE;
3- (3-BUTOXY-1,2, 5-THIADIAZOL-4-YD-1-AZABICYCLO [2.2.2]OCTANE; 3 - ( 3 -PENTYLTHIO- l , 2 , 5 -THIADIAZOL- 4 -YL ) - l -AZABICYCL0 - [ 2 . 2 . 2 J OCTANE ;
3- (3-ETHOXY-l,2, 5-THIADIAZOL-4-YL) -1-AZABICYCLO [2.2.2]OCTANE;
3- (3-HEXYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
3-(3-(3-PHENYLPROPYLTHIO)-l,2,5-THIADIAZOL-4-YL)-l- AZABICYCLO [2.2.2JOCTANE;
3- (3-HEXYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[2.2.2]OCTANE;
3- (3- (4-CYANOBENZYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2]OCTANE;
EXO-6- (3-CHLORO-l, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-HEXYLTHIO-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6-(3- (5-HEXENYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6- (3-PENTYLTHIO-l,2, 5-THIADIAZOL-4-YL) -1- AZABICYCLO[3.2.1]OCTANE;
ENDO-6-(3-ETHYLTHIO-l,2,5-THIADIAZOL-4-YL)-l- AZABICYCLO[3.2.1JOCTANE; and ENDO-6- (3- (3-PHENYLPROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1-
AZABICYCLO[3.2.1JOCTANE; or a pharmaceutically acceptable salt or solvate thereof.
73. A method of Claim 71 wherein the Compound is 3- (3-BUTYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1- AZABICYCL0[2.2.2]OCTANE; or a pharmaceutically acceptable salt or solvate thereof.
74. A composition of Claim 69 wherein the Compound is of Formula II.
75. A composition of Claim 74 wherein the Compound of Formula II is selected from the group consisting of
3- (3-METHOXY-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-ETHOXY-1,2, 5-THIADIAZOL-4-YD-1,2, 5, 6-TETRAHYDRO-l- METHYLPYRIDINE
3-(3-PROPOXY-l,2,5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-BUTOXY-1,2, 5-THIADIAZOL-4-YL)l,2,5, 6-TETTRAHYDRO-l- METHYLPYRIDINE
3- (3-ISOPROPOXY-1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CYCLOPROPYLMETHOXY-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-PENTOXY-l,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE 3- (3-ISOBUTOXY-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-{3-BUTENOXY)-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (BUT-2-YNOXY) -1, 2 , 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (3-METHYLBUTOXY) -1, 2, 5-THIADIAZOL-4-YL) -1, 2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (PROP-2-YNOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BENZYLOXY-l,2,5-THIADIAZOL-4-YL)-l,2,5,6-TETRAHYDRO-l- METHYLPYRIDINE
3- (3-CHLORO-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-CHLORO-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDROPYRIDINE
3- (3-BUTOXY-l,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDROPYRIDINE
3- (3-ETHOXY-l, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-l- ETHYLPYRIDINE
3- (3-CHLORO-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-l- ETHYLPYRIDINE
3- (3-METHOXYETHOXY-1,2 , 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO- 1-METHYLPYRIDINE 3- (3-HEPTYLOXY-1,2,5-THIADIAZOL-4-YL) -1, 2 , 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (3-PENTYNYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-PENTENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-PROPENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-OCTYLOXY-l,2,5-THIADIAZOL-4-YL)-l,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (3-HEXYNYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-BUTENYL-2-OXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYL-PYRIDINE
3- (3- (4-HEXENYLOXY(-1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
TRANS-3- (3- (3-HEXENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3- (3- (2-PENTENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
CIS-3-(3- (2-HEXENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-(5-HEXENYLOXY)-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE CIS-3- (3- (3-HEXENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,4,5- TETRAHYDRO-1-METHYLPYRIDINE
TRANS-3- (3- (2-HEXENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-METHYLPIPERIDINO-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-MORPHOLINO-1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-DIMETHYLAMINO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3-HEXYLAMINO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL-4-YD -1,2, 5, 6-TETRAHYDRO-1- DEUTEROMETHYLPYRIDINE
1,2, 5, 6-TETRAHYDRO-3- (3-HEXYLOXY-l, 2, 5-THIADIAZOL-4- YL) PYRIDINE
3- (3- (2- (2-METHOXYETHOXY) -ETHOXY) -1,2,5-THIADIAZOL-4-YL) - 1,2 , 5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-(3-ETHOXY-l-PROPOXY)-l,2,5-THIADIAZOL-4-YL) -1,2,5,6,- TETRAHYDRO-1-METHYLPYRIDINE
3- (2-ETHOXYETHOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO- 1-METHYLPYRIDINE
3- (3- (2-BUTOXYETHOXY) -1, 2, 5-THIADIAZOL-4-YL)-1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3- (2- (2-BUTOXYETHOXY) -ETHOXY) -1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2- (2-ETHOXYETHOXY) -ETHOXY) -1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-METHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1■ METHYLPYRIDINE
3- (3-PENTYL-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1• METHYLPYRIDINE
3- (3-HEXYLTHIO-l,2,5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PENTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-ETHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-OCTYLTHIO-1,2, 5-THIADIAZOL-4-YD-1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYL-l,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3-(3-HEPTYL-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE 3- (3- (5-HEXENYL) -1,2, 5-THIADIAZO -4-YL) -1,2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-OCTYL-1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYPYRIDINE
3- (3- (2-METHYL) -BUTYL-1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-METHYLCYCLOPROPYL-l,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-CYCLOPENTYLTHIO-l,2, 5-THIADIAZOL-4-YD -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (1-ETHYLTHIO-2-METHOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-CHLORO-1-PROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-METHOXYETHOXY) -ETHYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3-(3-CYANO-l-PROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-BENZYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3- (2-ETHOXY-1-ETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3-(3-(4-PENTYNYLTHIO)-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3- (2- (2-ETHOXYMETHOXY) -ETHYLTHIO) -1,2, 5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (5-CYANO-l-PENTYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-PHENYL-1-PROPYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-PHENOXYETHYLTHIO)-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (4-CYANOBUTYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (2-ETHYLBUTYLTHIO)-l,2,5-THIADIAZOL-4-YD-l,2,5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-CYCLOHEXYLMETHYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (8-HYDROXYOCTYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1, 2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (7-OCTENYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3-CYCLOPROPYLMETHYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3 (3-CYCLOPROPYLMETHYLTHIO) -1,2, 5-THIADIAZOL-4-YD-1,2, 5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3-BUTENYLTHIO) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3- (4-PENTENYLTHIO)-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (4-ISOHEXYLOXY-1,2,5-THIADIAZOL-3-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
l-METHYL-1,2,5, 6-TETRAHYDRO-3- { (4-CYCLOPENTYLPROPYL)OXY) - 1,2,5-THIADIAZOL-3-YL) PYRIDINE
l-METHYL-1,2,5, 6-TETRAHYDRO-3- (4-ISOHEPTYLOXY-l, 2, 5- THIADIAZOL-3-YD PYRIDINE
l-METHYL-1,2, 5, 6-TETRAHYDRO-3- (4 ( (2-CYCLOHEXYLETHYL)OXY) - 1,2,5-THIADIAZOL-3-YL) PYRIDINE
1,2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (1-METHYLHEXLOXY) -1,2,5- THIADIAZOL-3-YL) PYRIDINE
3- (4- (l-ETHYLPENTYLOXY)-l,2, 5-THIADIAZOL-3-YD -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
3- (4- (1-ETHYLBUTOXY) -1,2, 5-THIADIAZOL-3-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
l,2,5,6-TETRAHYDRO-l-METHYL-3- (4- (1-METHYLPENTYLOXY) -1,2,5-
THIADIAZOL-3-)YL)PYRIDINE
l-METHYL-3-(4-(5-HEXENYLOXY) -1,2, 5-THIADIAZOL-3-YL) -1,2,5,6- TETRAHYDROPYRIDINE
1,2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLBUTOXY) -1,2,5- THIADIAZOL-3-YD PYRIDINE
1,2, 5, 6-TETRAHYDRO-1-METHYL-3- (4- (2-METHYLPENTYLOXY) -1,2,5- THIADIAZOL-3-YL) PYRIDINE 1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- (2 ,2, 2-TRIFLUOROETHOXY) - 1,2,5-THIADIAZOL-3-YL)PYRIDINE
1-METHYL-l,2,5, 6-TETRAHYDRO-3- (4- (3-METHYLPENTYLOXY) -1,2, 5- THIADIAZOL-3-YL) PYRIDINE
3- (3- {3-METHYL-2-BUTENYLOXY) -1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDO-1-METHYLPYRIDINE
3- (3-ISOBUTOXY-l,2,5-THIADIAZOL-4-YL)-l,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4-(2-METHYLBUTOXY) -1,2,5- THIADIAZOL-3-YL) PYRIDINE
3- (3- (3-HYDROXYPROPOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
(+-)l,6-DIMETHYL-3-(3-HEXYLOXY-l,2,5-THIADIAZOL-4-YL) - 1,2,5,6-TETRAHYDROPYRIDINE
3- (3- (3-PHENYL-ETHYLTHIO)-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
BIS-1,4- (3- (1-METHYL-1,2, 5, 6-TETRAHYDROPYRIDIN-3-YD -1,2,5-
THIADIAZOL-4-YL)BUTANEDITHIOL
3- (3- (4, 4, 4-TRIFLUOROBUTOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2, 5- THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3- (3- (3,3,3-TRIFLUOROPROPYLTHIO)-l,2,5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDRO-1-METHYLPYRIDINE
3-(3-PROPYLTHIO-l,2,5-THIADIAZOL-4-YL)-l,2,5,6- TETRAHYDROPYRIDINE 3- (3-BUTYLTHIO-1,2,5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1, 1- DIMETHYLPYRIDINIUM IODIDE
(+-)l,6-DIMETHYL-3-(3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDROPYRIDINE
(+-)1, 6-DIMETHYL-3- (3-BUTOXY-1, 2, 5-THIADIAZOL-4-YL) -1, 2 , 5, 6- TETRAHYDROPYRIDINE
3- (3- (3-METHYL-2-BUTENYLOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDO-1-METHYL PYRIDINE
3- (3-ISOBUTOXY-l,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1- METHYLPYRIDINE
1,2,5, 6-TETRAHYDRO-1-METHYL-3- (4- {2-METHYLBUTOXY) -1,2,5- THIADIAZOL-3-YL)PYRIDINE
3- (3- (3-HYDROXYPROPOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDRO-1-METHYLPYRIDINE
(+-) 1, 6-DIMETHYL-3- (3-HEXYLOXY-1, 2, 5-THIADIAZOL- -YL) - 1,2,5, 6-TETRAHYDROPYRIDINE
3- (3- (3-PHENYL-ETHYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE
BIS-l,4-(3-(l-METHYL-1,2,5,6-TETRAHYDROPYRIDIN-3-YL) -1, 2, 5- THIADIAZOL-4-YL)BUTANEDITHIOL
3- (3- (4,4, 4-TRIFLUOROBUTOXY) -1,2, 5-THIADIAZOL-4-YL) -1,2, 5, 6- TETRAHYDRO-1-METHYLPYRIDINE 3- (3- (3,3,3-TRIFLUOROPROPYLTHIO) -1, 2, 5-THIADIAZOL-4-YL) - 1,2,5, 6-TETRAHYDR0-1-METHYLPYRIDINE
3- (3-PROPYLTHIO-1, 2, 5-THIADIAZOL-4-YL) -1, 2, 5, 6-TETRAHYDRO-1- METHYLPYRIDINE
3- (3-PROPYLTHIO-l,2,5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5,6- TETRAHYDROPYRIDINE
3- (3-BUTYLTHIO-1,2, 5-THIADIAZOL-4-YL) -1,2,5, 6-TETRAHYDRO-1, 1- DIMETHYLPYRIDINIUM IODIDE
(+-) 1, 6-DIMETHYL-3- (3-BUTYLTHIO-1, 2, 5-THIADIAZOL-4-YL) - 1,2, 5, 6-TETRAHYDROPYRIDINE; and
(+-) 1, 6-DIMETHYL-3- (3-BUTOXY-1,2, 5-THIADIAZOL-4-YL) - 1,2, 5, 6-TETRAHYDROPYRIDINE; or a pharmaceutically acceptable salt or solvate thereof.
76. A composition of Claim 69 wherein the opioid compound is selected from the group consisting of morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton's cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine.
77. A composition of Claim 69 wherein the opioid compound is selected from the group consisting of hydromorphone, hydrocodone, meperidone, buprenorphine, butorphenol, nalbuphine, pentazocine, oxymorphine, oxycodone, levorphanol, fentanyl, and alphaprodine.
78. A composition of Claim 69 wherein the opioid compound is selected from the group consisting of propoxyphene, methadone, morphine, hydrocodone, hydromorphine, and codeine.
79. A composition of Claim 78 wherein the opioid compound is selected from morphine and codeine.
80. A method for treating pain comprising administering an analgesic dose of a composition comprising a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and one or more opioid compounds in a weight ratio of Compound to opioid compound of from about 1 to about 1000.
81. A method of Claim 80 wherein the Compound is of Formula I.
82. A method of Claim 81 wherein the Compound is 3- (3-BUTYLTHIO-l,2,5-THIADIAZOL-4-YL) -1- AZABICYCLO [2.2.2JOCTANE; or a pharmaceutically acceptable salt or solvate thereof.
83. A method of Claim 80 wherein the Compound is of Formula II.
81. The use of a composition comprising a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and one or more opioid compounds in a weight ratio of Compound to opioid compound of from about 1 to about 1000 for a manufacture of a medicament for therapeutic application in the treatment of pain.
82. The use of a composition comprising a
Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and one or more alpha-adrenergic compounds in a weight ratio of Compound to alpha-adrenergic compound of from about 1 to about 1000 for a manufacture of a medicament for therapeutic application in the treatment of pain.
83. The use of a composition comprising a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and one or more non-steroidal antiinflammatory drug (NSAIDS) in a weight ratio of Compound to NSAIDS compound of from about 1 to about 1000 for a manufacture of a medicament for therapeutic application in the treatment of pain.
84. The use of a composition comprising a Compound selected from the group consisting of Formula I and Formula II; or a pharmaceutically acceptable salt or solvate thereof; and acetaminophen in a weight ratio of Compound to acetaminophen of from about 1 to about 1000 for a manufacture of a medicament for therapeutic application in the treatment of pain.
PCT/US1996/019390 1995-12-07 1996-12-05 Method for treating pain WO1997020556A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IL12478696A IL124786A0 (en) 1995-12-07 1996-12-05 Method for treating pain
PL96327144A PL327144A1 (en) 1995-12-07 1996-12-05 Method of relieving paints
HU0000110A HUP0000110A3 (en) 1995-12-07 1996-12-05 Pharmaceutical compositions comprising azacyclic, azabicyclic or tetrahydro-pyridine-derivatives suitable for treating pain
NZ324594A NZ324594A (en) 1995-12-07 1996-12-05 A method and composition for treating pain using a composition comprising an azacyclic azabicyclic or tetrahydropyridine compound and an analgesic
CA002239732A CA2239732A1 (en) 1995-12-07 1996-12-05 Method for treating pain
JP09521436A JP2000501711A (en) 1995-12-07 1996-12-05 How to treat pain
AU11476/97A AU715645B2 (en) 1995-12-07 1996-12-05 Method for treating pain
EP96942906A EP0866702A4 (en) 1995-12-07 1996-12-05 Method for treating pain
EA199800535A EA199800535A1 (en) 1995-12-07 1996-12-05 METHOD OF TREATMENT OF PAIN
KR1019980704268A KR19990071977A (en) 1995-12-07 1996-12-05 How to treat pain
NO982582A NO982582L (en) 1995-12-07 1998-06-05 Procedure for the treatment of pain

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US829895P 1995-12-07 1995-12-07
US831295P 1995-12-07 1995-12-07
US831395P 1995-12-07 1995-12-07
US830695P 1995-12-07 1995-12-07
US831895P 1995-12-07 1995-12-07
US829595P 1995-12-07 1995-12-07
US831995P 1995-12-07 1995-12-07
US60/008,319 1995-12-07
US60/008,295 1995-12-07
US60/008,312 1995-12-07
US60/008,313 1995-12-07
US60/008,318 1995-12-07
US60/008,306 1995-12-07
US60/008,298 1995-12-07

Publications (2)

Publication Number Publication Date
WO1997020556A1 true WO1997020556A1 (en) 1997-06-12
WO1997020556A9 WO1997020556A9 (en) 1997-10-02

Family

ID=27567403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/019390 WO1997020556A1 (en) 1995-12-07 1996-12-05 Method for treating pain

Country Status (14)

Country Link
EP (1) EP0866702A4 (en)
JP (1) JP2000501711A (en)
KR (1) KR19990071977A (en)
CN (1) CN1208348A (en)
AU (1) AU715645B2 (en)
CA (1) CA2239732A1 (en)
CZ (1) CZ174598A3 (en)
EA (1) EA199800535A1 (en)
HU (1) HUP0000110A3 (en)
IL (1) IL124786A0 (en)
NO (1) NO982582L (en)
NZ (1) NZ324594A (en)
PL (1) PL327144A1 (en)
WO (1) WO1997020556A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559171B1 (en) 1999-06-04 2003-05-06 Eli Lilly And Company 7-oxo-2-azabicyclo[2.2.1]heptanes as selective muscarinic receptor antagonist
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US20220144817A1 (en) * 2019-02-22 2022-05-12 Karuna Therapeutics, Inc. Compounds and methods of deuterated xanomeline for treating neurological disorders
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115974863A (en) * 2021-10-14 2023-04-18 南京迈诺威医药科技有限公司 Malate of xanomeline derivative, crystal form A, preparation method of malate, and application of crystal form A

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041455A (en) * 1989-02-22 1991-08-20 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5527813A (en) * 1990-08-21 1996-06-18 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5605701A (en) * 1995-02-17 1997-02-25 Eli Lilly And Company Transdermal formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK198590D0 (en) * 1990-08-21 1990-08-21 Novo Nordisk As HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
WO1993014089A1 (en) * 1992-01-13 1993-07-22 Novo Nordisk A/S Heterocyclic compounds and their preparation and use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041455A (en) * 1989-02-22 1991-08-20 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5527813A (en) * 1990-08-21 1996-06-18 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5578602A (en) * 1990-08-21 1996-11-26 Novo Nordisk A/S Certain 1-azabicyclo[3.3.1]nonene derivatives and their pharmacological uses
US5605701A (en) * 1995-02-17 1997-02-25 Eli Lilly And Company Transdermal formulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOH L E: "OSTEOARTHRITIS", PHARMACOTHERAPY. A PATHOPHYSIOLOGIC APPROACH, XX, XX, 1 January 1989 (1989-01-01), XX, pages 899 - 911, XP001031517 *
See also references of EP0866702A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559171B1 (en) 1999-06-04 2003-05-06 Eli Lilly And Company 7-oxo-2-azabicyclo[2.2.1]heptanes as selective muscarinic receptor antagonist
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10639281B2 (en) 2013-08-12 2020-05-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10792254B2 (en) 2013-12-17 2020-10-06 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US20220144817A1 (en) * 2019-02-22 2022-05-12 Karuna Therapeutics, Inc. Compounds and methods of deuterated xanomeline for treating neurological disorders
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders

Also Published As

Publication number Publication date
NO982582L (en) 1998-08-03
NO982582D0 (en) 1998-06-05
PL327144A1 (en) 1998-11-23
HUP0000110A3 (en) 2000-09-28
CZ174598A3 (en) 1999-01-13
EA199800535A1 (en) 1998-12-24
KR19990071977A (en) 1999-09-27
JP2000501711A (en) 2000-02-15
CA2239732A1 (en) 1997-06-12
AU715645B2 (en) 2000-02-10
NZ324594A (en) 1999-09-29
CN1208348A (en) 1999-02-17
EP0866702A1 (en) 1998-09-30
HUP0000110A2 (en) 2000-06-28
EP0866702A4 (en) 2001-07-25
IL124786A0 (en) 1999-01-26
AU1147697A (en) 1997-06-27

Similar Documents

Publication Publication Date Title
US5945416A (en) Method for treating pain
US6444665B1 (en) Method for treating pain
US20060058333A1 (en) Analgesic compositions containing buprenorphine
EP0709095A2 (en) Method for treating anxiety using a tetrahydropyridine or azabicyclic oxadiazole or thiadiazole compound
BG63190B1 (en) The use of optically clean (+) norcisaprid for the treatment of emesis and disturbances of the central nervous system
EP0866702A1 (en) Method for treating pain
WO2017147104A1 (en) Muscarinic m2-antagonist combinations
WO1997020556A9 (en) Method for treating pain
Leppert Dihydrocodeine as an opioid analgesic for the treatment of moderate to severe chronic pain
AU705031B2 (en) Composition for treating pain
RU2419433C2 (en) Mediciation for prevention and treatment of alcohol dependence and dependence from medications
WO1998046227A1 (en) Composition for treating pain
WO1998046601A1 (en) Composition for treating pain
AU716972B2 (en) Method for treating bipolar disorder
US5726193A (en) Method for treating anxiety
MXPA98004525A (en) Method for treating do
MXPA98004519A (en) Composition to treat do

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96199835.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 111-125,CLAIMS,REPLACED BY CORRECTED PAGES 111-125

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2239732

Country of ref document: CA

Ref document number: 2239732

Country of ref document: CA

Kind code of ref document: A

Ref document number: 1997 521436

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996942906

Country of ref document: EP

Ref document number: PV1998-1745

Country of ref document: CZ

Ref document number: PA/a/1998/004525

Country of ref document: MX

Ref document number: 1019980704268

Country of ref document: KR

Ref document number: 324594

Country of ref document: NZ

Ref document number: 98-01055

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 199800535

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1996942906

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-1745

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980704268

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019980704268

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996942906

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-1745

Country of ref document: CZ